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CHAPTER 1
Introduction
Drug development is a lengthy process that takes on average 12 years from discovery
to the market for an innovative drug (Kola and Landis, 2004). This results in high
costs for pharmaceutical companies (DiMasi et al. (2003)). The drug development
process involves diﬀerent phases: target discovery, animal studies, clinical develop-
ment, and regulatory approval. Target discovery is the ﬁrst step in the discovery
of a medicine and refers to identifying the biological origin of a disease, and the
potential targets for intervention. After the candidate drug is tested on animals to
evaluate its safety, we move to the clinical development where the drug is tested on
humans. In order to move from preclinical stages, which comprise in-vivo and in
vitro experiments, to the clinical phase, consisting of studies in humans, regulations
require speciﬁc pre-clinical safety and eﬃcacy assessments. Regulatory agencies,
such as the Food and Drug Administration (FDA) and the European Medicines
Agency (EMA), are responsible for new drug approvals in the USA and European
Union, respectively. These agencies examine the results of the safety and eﬃcacy
studies conducted during drug development.
Regardless of the high development costs, the rate of new drugs ﬁnally entering the
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market remain low. Indeed, using data from ten large US and European pharma
companies, Kola and Landis (2004) report that only 11% of all the submitted com-
pounds had been approved by the European and/or the US regulatory authorities
between 1991 and 2000. Most worrying is the failure rate for compounds already in
Phase III trials, which is about 45%. In a recent follow-up study by DiMasi et al.
(2016), the authors estimated around 12% for the overall probability of success (i.e.
the likelihood that a drug in clinical phase is approved). The associated risks highly
increase the costs per approved drug.
According to Kola and Landis (2004), the success rate varies considerably between
diﬀerent therapeutic areas: cardiovascular drugs, for instance, have 20% success
rate, whereas only 8% of the compounds for central nervous system disorders suc-
cessfully pass from ﬁrst-in-man to registration stage. In other therapeutic areas,
such as women’s health, the failure rate at the registration stage is as high as 42%,
and in oncology it is about 30%. Approximately 62% of the compounds undergoes
attrition in Phase II trials. In this phase, cancer treatments face the highest failure
rate, with more than 70% of the oncology compounds failing at this stage.
Major causes of attrition are the lack of eﬃcacy accounting for approximately 30%
and toxicology and clinical safety accounting for a further approximately 30% of
failures. Denayer et al. (2014) and McGonigle and Ruggeri (2014) discuss extensively
about the translational value of animal experiments. The authors emphasize that
failures during phases II and III can be decreased by setting more stringent success
criteria for the non-clinical stages and by generating more predictive animal models.
Drug development is even more complicated by the fact that, despite the eﬀorts
made to develop eﬀective and safe medications, drugs often do not have the same
outcomes in all patients. Some patients may respond well to a given treatment, oth-
ers may not get any beneﬁt, whilst for others the treatment can even be harmful.
Individualized medicine oﬀers a chance to pinpoint patients that respond diﬀerently
to treatment because of speciﬁc biological and genetic features. In addition, individ-
ualized medicine allows to identify diﬀerent patient populations since early stages of
3drug development, and run trials that speciﬁcally target the responsive subgroup,
potentially leading to signiﬁcant results.
Biomarkers and precision medicine in drug development
In the era of personalized medicine, a growing variety of single and, more often,
panels of biomarkers allow us to better understand health, risk factors, and disease
mechanisms. According to the National Institutes of Health Biomarkers deﬁnition
Group, a biomarker ”is a characteristic that is objectively measured and evaluated as
an indicator of healthy biological processes, pathological processes, or pharmacologi-
cal responses to therapeutic intervention” (Biomarkers Deﬁnitions Working Group,
2001). Also the EMA has emphasized the importance of biomarkers (EMA, 2009),
(EMA, 2009) stating that they play an increasingly important role in the develop-
ment of new medicines and that their use is expected to streamline the access to
new medicines.
In fact, today biomarkers are an integral part of drug development, as the design of
new trials relies on biomarkers that highlight diﬀerences in patients’ genetic proﬁles.
These diﬀerences are then used to match a drug with those subjects that are more
likely to beneﬁt from it. Currently, biomarkers are notably employed in oncology
research to select the most appropriate therapy according to the genomic characteri-
zation of individual tumours, and their use will likely increase in the near future. An
example is breast cancer, where the treatment is often decided depending on a range
of genetic traits, such as the status of the estrogen receptor gene, the ampliﬁcation
of the epidermal growth factor receptor 2 (HER2) gene and gene-expression proﬁles
indicating the prognostic aggressiveness of the disease.
Buyse et al. (2011) provides deﬁnitions of diﬀerent types of biomarkers used in drug
development and cancer research. A prognostic biomarker gives information on the
likely course of a disease in an untreated individual. That is, prognostic biomark-
ers foresee the prognosis of individual patients. Predictive biomarkers are used to
predict how a patient will respond to a speciﬁc treatment. The baseline value of a
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predictive biomarker must be shown to predict the eﬃcacy or toxicity of a treatment,
as assessed by a deﬁned clinical end point. In other words, prognostic biomarkers
predict the outcome in a natural cohort and predictive biomarkers predict the eﬀect
of an experimental treatment compared to a control group.
To validate a predictive biomarker, its ability to predict the eﬀects of a drug (or lack
thereof) should be demonstrated in multiple studies. Data from randomized trials
that include patients with both high and low levels of biomarker are required to
identify statistically signiﬁcant predictive markers. Although retrospective analyses
are sometimes suﬃcient to identify candidate predictive biomarkers and to incorpo-
rate them into trial design and clinical practice, prospective clinical trials may still
be required to provide deﬁnitive evidence (Buyse et al., 2011).
According to Zhang et al. (2018), biomarker based clinical trial designs are appealing
because they are more likely to succeed, by more accurately targeting the appropriate
population as deﬁned by the biomarker. In addition, they can lead to a shorter
development process. From an industry point of view, Lavezzari and Womack (2016)
argues that qualiﬁed biomarkers allow to enroll only speciﬁc patient subpopulations,
resulting in faster, cheaper, and more informative clinical trials, thus increasing the
speed to market of eﬀective treatment options. In enrichment trials, deﬁned as trials
for which only patients tested as marker-positive are enrolled, biomarkers help to
select a study population that will more likely to respond to a new drug. Therefore,
enrichment designs may reduce drug development time and costs. However, several
challenges, such as the predictability of biomarkers and the development of robust
biomarker assays, must still be overcomed before advanced biomarker-based designs
can be implemented in the clinic.
The importance of the use of biomarkers in reducing attrition rates and enhance
translatability, e.g. to infer the correct dosage or signal whether a molecular target
has been hit, was emphasized by Wehling (2009) who developed a score to assess
the predictive value of biomarkers per se. Attention was drawn in the quantiﬁca-
tion of the importance of biomarkers and personalized medicine in the assessment
5of translatability. The biomarker score (detailed in Wehling (2006)) is part of an
overall score assigned to the translatability assessment. This scoring system gives
an estimate of the translatability of an early drug project by including several pieces
of evidence from animal and human studies, biomarker validation, and pharmacoge-
nomics, among others. In Wehling (2011), the author presents two case studies and
further present eight case studies in Wendler and Wehling (2012), where the scor-
ing system has been successfully implemented. However, the translatability score is
based on subjective beliefs and awaits validation. The proposed scoring system pro-
duces results retrospectively, but the important element here is that it shows that
the early development and use of powerful biomarkers can considerably decrease the
risk in drug development.
Bayesian clinical trials
Since last decade, Bayesian methodology has been regarded as a useful statistical
method in clinical research because it can be easily adapted to accrue information
during trials. Bayesian approaches can ease the decision making process and allow
the design of smaller more informative trials. In addition, they can also be used
to make mid-course adjustments to the trial design, to stop a trial, or to shorten a
study (Berry, 2006). Bayesian analysis also allows to integrate historical information
and synthesize results of several trials.
The FDA issued the ”Guidance for the Use of Bayesian Statistics in Medical De-
vice Clinical Trials” to guide the design of clinical trials for medical devices (FDA,
2010). Neither European nor Japanese regulatory authorities have introduced such
documents for Bayesian statistical methods in clinical trials. Although the FDA’s
guidance indicates some additional conditions to use Bayesian statistics for medical
devices i) prior information should be discussed with the FDA prior to the initiation
of a study, and ii) indications of the device may be impacted by modiﬁcations at the
interim analysis, the Bayesian framework oﬀers clear advantages over its frequentist
counterpart. For instance, traditional statistical methods take into account informa-
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tion from previous studies only at the design stage. Bayesian statistics instead can
incorporate information gathered before, during, and outside the trial. Furthermore,
Bayesian methods allow to monitor the trial more frequently and to make interim
decisions as soon as suﬃcient evidence is obtained.
The use of Bayesian methodology has been encouraged and has increased in the
pharmaceutical industry, especially in early clinical settings. However, the method-
ology seems to have far less impact on preclinical in vivo studies. This is rather
surprising in the context of regularly repeated in vivo studies where there is a con-
siderable amount of data from historical control groups which has potential value.
Besides preclinical and clinical research, the Bayesian approach can also be applied
during post-marketing surveillance and for meta-analysis. Moreover, recent advance-
ments in both computational algorithms and computer hardware have considerably
increased the feasibility of Bayesian computational methods.
Contribution and Purpose of the thesis
In this dissertation, we present diﬀerent statistical topics related to the usability
and applicability of biomarkers in clinical drug development. The development of
methods aiming to be used in translational research, has been a strong motivation
for this thesis. Even though the chapters cover a wide range of statistical method-
ologies, it is important to emphasize the features in common to the topics discussed.
First, all results can be appliedin diﬀerent phases of drug development, both in clin-
ical and pre-clinical areas. That means that we focused on methods that can be
used to incorporate preclinical reslults into the selection of biomarkers in clinical
development. Second, this thesis provides a framework to quantify the uncertainty
in variable selection and consequently in decision-making (e.g. decisions on selection
of a cutoﬀ for distinguishing biomarker negative and positve patients)
The main objectives of this cumulative thesis are summarized below:
1. We propose a method to select biomarkers, discuss the trade-oﬀ between parsi-
7mony and classiﬁcation performance of the resulting model and explain under
which conditions the method can be applied in clinical practice.
2. Based the observed score for each individual, that is derived from the selected
biomarkers, we aim to develop an eﬃcient estimation method to select cut-
points that take into account the clinical utility of a diagnostic test. The
methodology can be generalized and also applied to patient screening or patient
selection in enrichment studies.
3. We propose a Bayesian variable selection method that simultaneously perform
variable selection and cutoﬀ estimation (of the selected variables) by control-
ling the clinical utility, in a way that the predictors in the ﬁnal model are
selected under constrained predictive values.
4. Apply this methodology to real data sets of clinical practice and ﬁnally to
suggest new interesting lines of future research.
The thesis is structured as follows. In the ﬁrst part, we introduce a new method
for biomarker identiﬁcation in clinical environment. We present a method to select
biomarkers that aims to reduce the complexity of the model, i.e. the dimensionality
of the model, while keeping the classiﬁcation accuracy of the model as high as
possible. Our method encourages sparsity through the combination of the L0 with
L1-norm regularization of the model parameters. Although the combination of the
L0 with L1-norm regularization was ﬁrstly introduced by Liu and Wu, the use of
their method was restricted to moderate-sized data sets ( p << n) (Liu and Wu
(2007)). Instead, by considering a stepwise method for variable selection, we are
able to apply the combined penalty function to high-dimensional settings. We also
consider the combination of the L0 with L2-norm to account for the grouping eﬀect.
This means that, if in the dataset there is a group of correlated predictors, the
L2 norm tends to include or exclude simultaneously the group of the correlated
variables. In contrast, the L1 norm will select only a “representative” variable from
a group of correlated predictors.
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In early clinical development with limited sample size, statistical methods for in-
corporating results from animal models in early clinical trials are needed. It is of
high importance that the development of biomarker assays should be initiated early
in drug development process to be able to bridge later phases of clinical biomarker
assessment. If prior knowledge from preclinical research is available, it should be
utilized and incorporated in the selection process of biomarkers. A Bayesian frame-
work that facilitates incorporation of prior information is considered in Chapter 3
and Chapter 4.
In Chapter 3, we discuss the cutoﬀ selection of a biomarker assay. Continuous
diagnostic tests (biomarkers or risk scores) are often used to discriminate between
healthy and diseased populations. For the clinical application of such tests, the
key aspect is how to select an appropriate cut-oﬀ, or threshold value, which deﬁnes
a population that is more likely to respond to a treatment and a group of non-
responders. For example, in enrichment studies, estimating a cutoﬀ value such that
the subsequent patient enrollment in a trial will depend on that value, is a very
critical step.
As mentioned by Simon (2010) and adopted in this thesis, the term clinical utility
refers to the applicability of a biomarker test to improve the outcome for patients.
Improved outcome means that patients live longer, or that the treatment yields to
the same eﬀect of another drug but shows fewer adverse events. Clinical validation
of a test is often accompanied by calculating the sensitivity of the test for the identi-
ﬁcation of responders and the speciﬁcity for identifying nonresponders, respectively.
Sensitivity and speciﬁcity are useful measures to quantify the diagnostic ability of a
test, however, they do not provide relevant information when making a clinical de-
cision. By contrast, predictive values, the Positive Predictive Value (PPV) and the
Negative Predictive Value (NPV), which are functions of sensitivity, speciﬁcity and
the prevalence of the disease, are more useful measures to make clinical decisions
and quantify the clinical utility of the biomarker-based test. Overall, the clinical
utility of a test is a more informative and useful measure (than clinical validation)
to make therapeutic decisions.
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tribution of the cut-oﬀ and predictive values of a continuous biomarker. When
applying novel biomarkers into routine standard care, it is important to consider
risk thresholds to ensure the best possible decisions for every patient. Especially
in early oncology trials, integration of biomarker information to better demonstrate
eﬃcacy of a treatment and guide the design of following studies, is crucial. A good
example of how important is the choice of the cutoﬀ value and how biomarkers can
be applied to the clinic is described in Lunceford (2015), where he discusses cutoﬀ
selection as a criterion for patient enrolment in enrichment trials.
In our approach, we apply a Bayesian method to estimate the cutoﬀ value of a
biomarker assay by using the predictive values, and also determine the uncertainty
around these estimates. We use a step function, which serves as an approximate
model facilitating classiﬁcation into two groups that have diﬀerent response rates.
The advantage of using the step function is that both the cutoﬀ and the predictive
values are parameters of the model. Even if the assumption of a step function is
strong and the model is misspeciﬁed, the estimates of the assumed step function
are consistent for the parameter values for which the assumed model minimizes the
distance from the true distribution in terms of Kullback-Leibler divergence.
The proposed method works also well if we apply a constraint on the positive predic-
tive value of the test, namely to belong to a predetermined interval of high values,
e.g. between 80 and 100%. Equivalently the constraint can be applied to the NPV
of the test. We illustrate this approach by considering the previously described
Bayesian method and restricting the domain of the prior distribution to the desired
constrained interval. This optimization strategy provides the best classiﬁer with the
PPV in the pre-determined interval.
In the fourth chapter, we discuss the simultaneous variable selection and cutoﬀ
estimation (of the selected variables) by controlling the clinical utility, which is
expressed in terms of negative and positive predictive values. The selection of the
predictors in the ﬁnal model is done under the constraint that the predictive values
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can take values in prespeciﬁed interval. To address this method, the chapter couples
notions introduced in the second part of the thesis (estimation of the cutoﬀ and
predictive values) with ideas from the ﬁrst section about biomarker selection.
In a setting where multiple markers are available, we face the challenge of selecting
biomarkers for patient classiﬁcation that belong to the most important class. This
means that we select biomarkers such that the PPV (or analogously the NPV)
belongs to a prespeciﬁed set of values. Here we will consider the PPV over the
NPV as the important class. When using a Bayesian model and prior knowledge is
avaialble on which variables are more informative for the outcome, then this prior
information can be easily incorporated in the selection procedure.
To this end, Bayesian variable selection methods that use shrinkage priors, such
as the Laplace prior, the spike and slab, and the horseshoe prior, can be applied.
When applying frequentistic regularization methods, the most important aspect is
the tuning or selection of shrinkage parameters, as they control the trade-oﬀ be-
tween parsimony and predictability of the selected model. In a frequentist setting,
techniques like cross-validation are adopted to tune the shrinkage parameters. In-
stead of relying on cross validation for the tuning parameters, taking a Bayesian
perspective has the advantage that the penalty parameter can be marginalized over
the posterior distribution.
The Lasso estimates from a frequentist analysis (Tibshirani, 1996) can be interpreted
as posterior estimates, when the β’s have independent identical Laplace priors. Spike
and slab priors, the horseshoe, and the appropriate thresholding for inclusion prob-
abilities are also discussed in the third chapter. By assuming a step function to
model the probability of response, we incorporate in the selection algorithm the pa-
rameters of interest: the cutoﬀ and predictive values. Whilst in Chapter 3 we have
considered a single biomarker that was predictive for the outcome, in the multivari-
ate problem presented in Chapter 4, the proposed method simultaneously performs
variable selection and cutoﬀ estimation for the risk score taken here as the linear
predictor Xβ, where β is the vector of coeﬃcients of the selected biomarkers X.
CHAPTER 2
Model selection based on Combined penalties for Biomarker
identiﬁcation
Contributed material
Eleni Vradi, Werner Brannath, Thomas Jaki & Richardus Vonk (2017). Model
selection based on combined penalties for biomarker identiﬁcation. Journal of Bio-
pharmaceutical Statistics, 28 : 4, 735−749, DOI: 10.1080/10543406.2017.1378662
In Chapter 2, we discuss model selection in a penalized regression framework. We
explore diﬀerent penalization methods that are broadly used in the literature for
both regression and classiﬁcation. This is of particular importance as some of the
thorniest issues in drug development can potentially beneﬁt from the use of high di-
mensional data for biomarker selection. Indeed, the high costs and the long duration
for clinical development, coupled with high attrition rates, require the quantiﬁcation
of the risk associated with the transition from early- to late-stage development and
biomarkers play an important role in this quantiﬁcation. Thus, biomarkers panels
must be carefully selected at early stages of drug development, as this would aﬀect
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the later stages of the process.
Inspired by the work of Liu and Wu (2007) that proposed a model selection approach
that combines known penalty functions, we extent this idea to high-dimensional
settings by introducing a stepwise forward variable selection algorithm. We brieﬂy
discuss diﬀerent suitable optimization methods and conclude with some simulation
results that can be seen in the contributed material.
Preliminaries on penalization methods
From a statistical point of view, biomarker selection translates into statistical mod-
eling for variable selection. In practice, a large number of candidate predictors are
available for modeling. Keeping only the most relevant variables in the model im-
proves the interpretation and may enhance the predictability of the resulting model.
The correct classiﬁcation of variables as having (nearly) zero or non-zero eﬀects is
important in the ﬁeld of clinical development concerned with biomarker selection.
Inclusion of regressors with zero eﬀect will result in reduced predictive performance
of the resulting model and loss in estimation precision, whereas omitting regressors
with non-zero eﬀect will lead to biased estimates. Therefore, the ideal biomarker
selection method should aim to get rid of any irrelevant biomarkers and include in
the model the most important ones.
Especially in the framework of regularization methods, various penalty functions
are used to perform variable selection. Frank and Friedman (1993) proposed the
bridge regression by introducing the penalty of the form Lq =
∑d
j=1 |βj|q ,q > 0,
for the vector of regression coeﬃcients β = (β1, β2, . . . , βd) ∈ Rd. When q ≤ 1, the
penalty performs variable selection. The case in which q = 1 is the L1 penalty, and
it corresponds to the Least Absolute Shrinkage and Selection Operator (denoted as
’Lasso’) (Tibshirani, 1996). In this case, the penalty performs continuous shrinkage
and variable selection at the same time.
On the other hand, when q = 2, we get the ridge estimator (Hoerl and Kennard,
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1970) that shrinks coeﬃcients towards zero, without performing variable selection.
The limit of the Lq as q → 0 gives the L0 penalty, which penalizes the number of
non-zero coeﬃcients and, for this reason, is appealing for model selection, if sparse
models are of advantage. However, due to its non-convexity and discontinuity at
the origin, the corresponding optimization problem becomes diﬃcult to implement
in high dimensions.
In genomic research, an L1 penalty is routinely used due to its convexity and opti-
mization simplicity with regard to its numerical minimization also in high dimen-
sions. The Lasso in the context of parametric models consists of optimizing the
log-likelihood function subject to a constrained L1-norm of the model parameters.
It was originally introduced by Tibshirani (1996) for regression and it was proved to
simultaneously perform shrinkage and feature selection in linear regression models.
The L1-norm penalization shrinks irrelevant predictors to zero and thereby provides
sparse classiﬁers.
Lasso variable selection has been shown to be inconsistent in certain scenarios (Zou,
2006; Leng et al., 2006; Zhao and Yu, 2006; Yuan and Lin, 2007). Therefore, a
new version of the Lasso was introduced, called the adaptive Lasso, where adaptive
weights are used for penalizing diﬀerent coeﬃcients in the L1 penalty. Zou (2006)
showed that the adaptive Lasso enjoys the oracle properties namely it performs as
well as if the true underlying model was given in advance. For the latter model,
the objective function becomes −logL + λ∑dj=1wjL1(βj) with logL the likelihood
function, wj =
1
|β∗j |γ being the adaptive weights and β
∗
j the ridge regression estimator.
However, the result of the L1 type regularization may not be sparse enough for prac-
tical purposes and a good interpretation. Hence, the development of new methods
to obtain sparser solutions has become an essential goal in research on classiﬁcation
and feature selection. A variable selection method that combines the L1 and L0
penalties was proposed by Liu and Wu (2007). The authors used a mixed integer
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programming algorithm to optimize the objective function
− logL+ λCLα (2.1)
with CLα = αL1 + (1 − α)L0. The L0 term is a continuous approximation of L0
to ease the optimization. The results showed that the method achieved sparser
solutions than Lasso, as well as more stable solutions that the L0 regularization.
However, the application was limited to moderate dataset sizes, due to computa-
tional ineﬃciency for large-scale analysis. So far, other combinations of Lq penalties
have been proposed, for example by Zou and Hastie (2005) and more recently by
Huang et al. (2016), with each of these methods using diﬀerent optimization algo-
rithms to approach the solution.
In feature selection problems, when biomarkers (e.g. genes) are involved in the same
biological pathway, the correlation between them can be high (Segal et al., 2003).
Zou and Hastie (2005) proposed a new regularization term, the elastic net penalty,
namely (1 − α)L1 + αL2, with α ∈ [0, 1], which is a convex combination of the L1
and L2 penalties. Zou and Hastie’s work showed that in a regression framework a
group of highly correlated predictors can be selected with the elastic net. On the
other hand, Lasso fails to select the whole group of correlated variables, as it can
only select a subset of independent variables. If the aim is a sparse model, Lasso is
more appropriate method, as it will select one variable among a group of correlated
predictors.
Optimization Methods
The optimization of the objective function −logL + λCLα is rather challenging
since CLα(β = αL1 + (1 − α)L0), is non-convex and non-diﬀerentiable at certain
points of the parameters’ space. The same challenge holds when we consider the
objective function −logL+λCL2α with CL2α(β) = αL2+(1−α)L0).The solution to
these multivariable optimization problems is often found by gradient-free algorithms.
15
Such a solution can be implemented when gradient evaluations are diﬃcult, or in
fact when gradients of the underlying optimization problem do not exist. Diﬀerent
methods that oﬀer this feature have been suggested, including Simulated Annealing
(Kirkpatrick et al., 1983), Diﬀerential evolution (Storn and Price, 1997), Nelder-
Mead (Nelder and Mead, 1965), and Hooke−Jeeves (Hooke and Jeeves, 1961).
Furthermore, in the class of numerical methods, the Broyden (1970)- Fletcher (1970)-
Goldfarb (1970)- Shanno (1970) (BFGS) variable metric (quasi Newton) method
was shown to work well in the optimization of non-smooth and non-convex func-
tions (Lewis and Overton, 2013). However, there is no guarantee that the algorithm
converges to the optimal solution. A more detailed review of gradient-free algo-
rithms can be found in Rios and Sahinidis (2013) and Lewis et al. (2000). Among
the methods mentioned above, we used the Hooke−Jeeves (HJ) and the BFGS to
solve our optimization problem and we report our empirical results which motivated
us to develop the proposed stepwise forward method for variable selection.
In the class of direct search methods, the method of Hooke−Jeeves is based on
function evaluations using discrete steps and ﬁxed search stepsizes, which are re-
duced depending on the success of the steps of the algorithm. Repeated searches
are performed according to a cyclic coordinate search pattern, followed by a search
pattern that is deﬁned by the diﬀerence between the starting and ending points
of each cyclic coordinate search. On the other hand, the BFGS method uses an
approximation of the Hessian matrix in order to ﬁnd the stationary points of the
function to be minimized. The ability to capture the curvature information of the
considered function makes the BFGS method very eﬃccient.
We applied both the HJ and BFGS algorithms, and we compared their performance
in the global optimization and in the stepwise forward method. Regarding the mini-
mization of (2.1), our empirical results showed that when we used the HJ algorithm,
the value of the objective function was always smaller than the one resulting from
the BFGS method, keeping the values of the regularization parameters (α, λ) ﬁxed.
However, the BFGS method gave more stable solutions to the optimization problem.
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Indeed, the BFGS method always converged to the same solution when repeating the
optimization of (2.1), whereas the HJ algorithm was not stable, providing diﬀerent
results every time we optimized (2.1).
As mentioned by Frommlet and Nuel (2016), when the number of predictors d grow
large (i.e. d > 20), it is not possible to apply algorithms that guarantee to ﬁnd
the optimal solution (see also Furnival and Wilson, 1974). Instead, heuristic search
strategies, such as stepwise procedures, may be considered. By using heuristic tech-
niques, we can approximate the optimum solution for the non-smooth, non-convex
and NP-hard optimization problem of the equation (2.1), where exact algorithms
are not applicable.
Moreover, the issues observed in the behaviour of both optimization methods led
us to consider a heuristic stepwise algorithm to deal with model selection in high-
dimensional settings. Regarding the stepwise method, using any of the two opti-
mization algorithms, either HJ or BFGS, to minimize the penalized likelihood, our
empirical results showed that the values of the objective function were the same in
any case, resulting in the same solution.
The stepwise forward approach that we used for variable selection using the
penalized likelihood criterion for feature selection, means that candidate predictors
are sequentially included in the model, if the inclusion of a variable, on top of the set
of variables already in the model, improves the model ﬁt. The algorithm is described
in details in Vradi et al. (2017). For the stepwise model selection, we chose to use
the BFGS algorithm since it showed a faster convergence than the HJ algorithm. In
this stepwise forward selection framework, at each step we optimize the objective
function −logL + λα∑dj=1 L1(βj) using the BFGS algorithm, and perform model
selection using the L0 penalty.
The optimal regularization parameters were tuned by 10-fold cross-validation on
the two-dimensional surface (α, λ) using a grid of values. The choice of the optimal
parameters was done in a way ackowledging the fact that we are aiming for a com-
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promise between good classiﬁcation performance and low complexity of the model
(see details in Vradi et al. (2017)). To evaluate the classiﬁcation performance of
the methods we used the Brier score (Brier, 1950) as a measure for the accuracy of
predictions which is the squared distance between the observed statuses yi and the
predicted probabilities pˆi.
Conclusion
In the contributed paper, we have outlined a method for variable selection, which
penalizes the likelihood function with a linear combination of L0 and L1 or L2
penalties (CL,CL2) in a stepwise forward variable selection procedure. Our aim
was to obtain a sparser model than the one that can be generated by a method
that considers the L1 penalty alone. At the same time, we aimed to achieve a good
predictive performance. Therefore, we implemented a stepwise variable selection
approach, which at each step performed both shrinkage by using the L1 penalty and
model selection using the L0 criterion.
An advantage of the proposed method is that we no longer need to consider the
continuous approximation to the discontinuous L0 function and, thus can eliminate
the continuity parameter . Moreover, the importance of our stepwise approach is
highlighted by the fact that none of the state-of-the-art global optimization algo-
rithms for non-smooth and non-convex functions has so far achieved satisfactory
results.
Lastly, we showed in a simulation study and a real data application that our method
generated sparse models while maintaining a good classiﬁcation performance. This
is an essential consideration for classiﬁcation and screening applications, where the
goal is to develop tests by using as fewer features as possible to enhance the in-
terpretability and, potentially, the reproducibility of the results, as well as to con-
trol the costs of the test implementation. Our method showed satisfactory results
with regard to sparsity and classiﬁcation performance in terms of AUC of the ROC
curves and Brier score. An R-package stepPenal (R Core Team, 2015) was developed
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around this new method and is available on CRAN.
To conclude, we argue that our method provides a sparser model than the ones
obtained by alternative methods, and, at the same time, it maintains similar pre-
diction properties to the ones of other widely used methods, such as Lasso and
adaptive Lasso. Even though the stepwise method is just an approximation to the
true optimal solutions, it appears to approximate the true optimal solution as well
as, and sometimes even better, than the global optimization routine. Moreover, it
reduces the computational time considerably. Indeed, the ﬁne tuning of the regular-
ization parameters (α, λ) is an important aspect of penalization methods and can
be computationally intensive and time-demanding.
CHAPTER 3
A Bayesian approach to estimate the cutoﬀ and the clinical
utility of a biomarker assay
Contributed material
Vradi E, Jaki T, Vonk R, Brannath W (2018). A Bayesian approach to estimate the
cutoﬀ and the clinical utility of a biomarker assay. Statistical methods in medical
research. In press
In Chapter 3, we introduce a method for estimating the cutoﬀ value of a biomarker
assay. By using a Bayesian method, we can derive the posterior distribution for the
cutoﬀ and the predictive values of a diagnostic test. Firstly, we explain brieﬂy meth-
ods that are used for optimal cutoﬀ estimation, as well as the relation of prevalence,
sensitivity and speciﬁcity with predictive values. The method considers a binary
response but it can be extented to time-to-event outcomes as well and we give a real
data example of the proposed method on survival data.
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Preliminaries in diagnostic tests
In biomedical research, quantitative tests or biomarkers are often used for diagnostic
or screening purposes. In fact, these tests simplify binary classiﬁcations by setting
a cut-oﬀ value on the biomarker measurements. The Receiver Operating Character-
istic (ROC) curve is a popular graphical method for displaying the discriminatory
accuracy of a marker. It is employed to identify two diﬀerent populations and ex-
amine the eﬀectiveness of continuous diagnostic markers, as it distinguishes between
diseased (positive test, T+) and healthy individuals (negative test, T−). The ROC
curve is a plot of sensitivity Se(c) and 1 − Sp(c) over all possible threshold values
c of the marker. The area under the ROC curve (AUC) is used to evaluate the
discriminatory ability of a given marker, i.e. how well the marker can distinguish
between diseased and healthy individuals.
The classiﬁcation of the true status of a patient (healthy or diseased) based on
any diagnostic test is not error-free. Thus, it is necessary to measure the errors in
order to assess the diagnostic validity of the test, that is, to evaluate its diagnostic
accuracy or ability to diﬀerentiate between two populations. The test may fail in two
diﬀerent ways: by incorrectly classifying a healthy patient (a false positive, denoted
by FP ) or, alternatively, by deﬁning a subject as healthy when he or she is in fact
diseased (a false negative, denoted by FN).
Table 3.1: Classiﬁcation of disease results by disease status
True disease Status
Test Results Diseased (Y=1) Healthy (Y=0) Total
Positive (T+) True Positive TP False Positive FP TP+FP
Positive (T−) False Negative FN True Negative TN FN+TN
TP+FN FP+TN N
The evaluation of a positive or negative test result is determined by a threshold, or
cut-oﬀ value, that needs to be set on (the measurement scale of) the biomarker assay.
The cutoﬀ is a value that deﬁnes two diﬀerent classes of observations according to
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their biomarker score. For instance, a test result is positive if the biomarker value
exceeds the cutoﬀ, i.e. X > c then T+. On the other hand, the test is negative when
the measured value is below the cutoﬀ, i.e. X ≤ c then T−. Optimal cut-oﬀ points
are often set by using criteria derived from ROC curves. However, it is important
to keep in mind that generally, one cannot talk in absolute terms of a ”best choice”
of cutoﬀ c, as the optimal cut-oﬀ depends on the situation which is to be used. As
discussed in Perkins and Schisterman (2006) optimal thresholds may vary depending
on the underlying criteria.
Figure 3.1: (A) Plot of probability density functions of healthy and diseased pop-
ulations (B),(C) Diﬀerent cut-oﬀ points result in diﬀerent classiﬁcation
errors. The blue shadowed area depicts the False Positives (FP) and the
black shadowed area the False Negatives (FN)
In diagnostic tests with continuous measurements, selecting the optimal cut-oﬀ is an
important task. As shown in Figure 3.1, diﬀerent cut-oﬀ scores c determine diverse
frequencies of correct and incorrect diagnosis. In general, there is a range of potential
test results for which the distributions of healthy and diseased subjects overlap. If
we want to increase the probability of detecting diseased patients by moving the
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cutoﬀ to the left-hand side of the plot, the number of false positives also increases.
On the other hand, if the cutoﬀ is moved towards the right-hand side, the number of
false positives decreases at the expense of more false negative results. Therefore, as
sensitivity decreases, speciﬁcity increases, and vice versa. Hence, when selecting the
“best” cutoﬀ c, we seek for a balance between sensitivity and speciﬁcity measures.
In the literature, we ﬁnd diﬀerent optimality criteria that have been suggested to
select the best threshold value. Indeed, there are several methods to determine
optimal cut-oﬀ values. For example, there are diﬀerent well-known criteria that
use the ROC curve, such as the Youden index and the Euclidean index, see e.g.
Fluss et al. (2005), Magder and Fix (2003). The Youden index (J), one of the
most frequently used methods, maximizes the sum of the two correct classiﬁcation
probabilities, i.e J = maxc{Se(c) + Sp(c)− 1}
There are also measures that rely on the maximization of the diagnostic odds ratio
(DOR) function Glas et al. (2003), deﬁned as the ratio between the odds of TPR
and FPR over all possible cut-point values of X. Bo¨hning et al. (2011) has showed
that the DOR strategy is no longer recommended since it might easily lead to the
choice of cut-oﬀ values on the boundary of the parameter range of X.
However, ROC based methods do not provide information on the diagnostic accuracy
for speciﬁc patients. The use of sensitivity and speciﬁcity was criticized for example
by Moons and Harrell (2003), claiming that sensitivity and speciﬁcity are not the
correct parameters to characterize diagnostic accuracy, as these parameters are of
limited relevance to practice. According to the authors, the characteristics of a test
should rather be evaluated based on the actual patient population. Especially when
a diagnostic test is used for classiﬁcation purposes, clinicians are mainly concerned
about the predictive ability of the test.
The assessment of correct classiﬁcations can be facilitated by the use of positive
and negative predictive values (PPV and NPV, respectively). PPV and NPV are
functions of the accuracy of the test and of the overall prevalence of the disease.
Therefore, they can be used to deﬁne the clinical utility of a diagnostic test for
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classiﬁcation purposes in a speciﬁc population. The positive and negative predictive
values are deﬁned as PPV = P (Y = 1|T+) and NPV = P (Y = 0|T−).
The positive predictive value (PPV), or the predictive value of a positive test, is
the probability of developing a disease (or responding to a treatment) when the test
result is positive. Hence, the positive predictive value can be estimated based on
the proportion of patients with a positive test result that ultimately proved to be
diseased (Y=1). From Bayes theorem, the PPV is expressed in terms of sensitivity
(Se) and speciﬁcity (Sp) measures, and the prevalence π of the disease under study:
PPV =
πSe
πSe+ (1− Sp)(1− π) =
TP
TP + FP
(3.1)
where the sensitivity Se = P (T+|y = 1) and 1−Sp = P (T+|y = 0). The prevalence
of the disease is π = P (Y = 1). Analogously, the NPV can be expressed in terms of
sensitivity, speciﬁcity and prevalence as:
NPV =
(1− π)Sp
π(1− Se) + Sp(1− π) =
TN
FN + TN
(3.2)
and the complementary 1-NPV is given by
1−NPV = π(1− Se)
π(1− Se) + (1− Sp)(1− π) =
FN
FN + TN
Similarly to the Youden index, that can be considered as a summary measure of the
ROC curve, the predictive summary index (PSI) can be seen as a summary index of
the predictive ROC (PROC) curve (Linn and Grunau (2006)). Analogously to the
ROC, the PROC is a plot of the PPV versus 1-NPV over a range of cutoﬀ values c.
For any threshold c, the PSI is deﬁned as:
PSI(c) = PPV (c) +NPV (c)− 1.
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Obviously, PSI ∈ [0, 1]. The threshold value c∗ that maximizes PSI(c) may be
selected as the optimal cutpoint, that is c∗ = argmaxc{PSI(c)}. The PSI provides
a criterion to choose an optimal cut-oﬀ value that takes the predictive values into
account. The criterion describes the likelihood of correctly diagnosing a diseased
patient after a positive test result, while at the same time it indicates how likely is
to misdiagnose a patient with a disease after a negative test. It is important to note
that a test with high sensitivity and speciﬁcity may have a low positive predictive
value if applied to low prevalence populations.
Figure 3.2: Plot of the predictive values for varying values of prevalence and ﬁxed
sensitivity=0.9 and speciﬁcity=0.8
In order to illustrate the impact of the prevalence on the clinical utility of a test,
we have plotted in Figure 3.2 the PPV and NPV over a range of prevalence values
for ﬁxed sensitivity and speciﬁcity using the expressions in formulas (3.1) and (3.2).
Assuming a test with 80% speciﬁcity and 90% sensitivity (both of which are theo-
retically independent of prevalence), we see that at low prevalence, a negative test
result is more likely to be true than a positive result. This plot shows the recipro-
cal relationship between PPV and NPV: when prevalence increases, the PPV raises
while the NPV decreases. It also points out the potential loss of PPV in case a test
is used in a context of low disease prevalence, rather than in populations with a high
disease prevalence.
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Figure 3.3 shows how altering either sensitivity or speciﬁcity aﬀects the predictive
values of a test at three diﬀerent values of prevalence (π = 0.1, π = 0.5 and π = 0.7).
As we see, in case of a low prevalence disease, the PPV is less inﬂuenced by a loss of
sensitivity than a loss of speciﬁcity. Moreover, there is a positive correlation between
NPV and speciﬁcity (i.e the rate of false positives is low).
Figure 3.3: Plot of the predictive values for ﬁxed speciﬁcity and varying sensitivity
(left panel) and ﬁxed sensitivity and varying speciﬁcity (right panel)
where we consider a prevalence of 0.1 (solid line), 0.5 (dashed line) and
0.7 (dotted line). PPV and NPV are depicted in black and red lines,
respectively.
Bayesian methods for cutoﬀ estimation
Lately, Subtil and Rabilloud (2010) introduced a Bayesian method for estimating
both the optimal cut-point of a quantitative marker and its credible interval, when
the diagnostic test is based on optimizing a utility function of parameters including
prevalence, sensitivity, speciﬁcity, net beneﬁt, and net costs of the test. First, the
authors assumed that the biomarker values follow normal distributions for the two
populations, i.e. N(μH , σ
2
H) for the healthy and N(μD, σ
2
D) for the diseased subjects.
Assuming non-informative priors for the parameters (mean and variance for the
diseased and non-diseased groups), they used an MCMC algorithm to sample from
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the posterior distribution of μH , μD, σH , σD. Then, for each obtained sample in the
MCMC chain, they optimized the utility function
U(c) = 1− Φ(c− μD
σD
) +RΦ(
c− μH
σH
)
where Φ denotes the standatrd normal distribution function and R is a function of
the prevalence and net cost and net beneﬁt. The estimated optimal cutoﬀs over all
samples form the posterior distribution of the optimal cutoﬀ. To deal with variance
or mean heterogeneity, Subtil and Rabilloud (2014) extended this Bayesian method
to diﬀerent biomarker population distributions like the student-t distribution or a
mixture of Dirichlet distributions.
Lunceford (2015) discussed the estimation of the clinical utility of a biomarker assay
in the context of predictive enrichment studies in the oncology ﬁeld. According to
the author, the key point is that enrichment involves an additional biomarker-based
inclusion criterion with the aim to treat those who are more likely to respond.
The motivation of this study was to select a cut-oﬀ value for a potential predictive
biomarker that could be used as a criterion to enroll patients. The author proposed
a method based on the integral representations of clinical utility measures. By
implementing a Bayesian approach to assess clinical utility measures, he facilitates
cutoﬀ decision-making, without considering the actual cutoﬀ estimation.
In the contributed paper, we proposed a Bayesian method to estimate the cutoﬀ of
a biomarker assay, and more importantly the uncertainty around this estimate. We
assumed that the probability of response can be modeled by a step function to fa-
cilitate the decision-making process regarding, for example, the selection of patients
that were more likely to respond to a personalized treatment. We used a step func-
tion to model the probability of response, which served as an approximate model to
facilitate the classiﬁcation of patients into two groups with pronounced diﬀerences
in their response rates. For a single biomarker X and a vector of n responses Y , we
modeled the response probability as p(x) = P (Y = 1|X) =  {x≤cp}p1 +  {x>cp}p2,
where p1 , p2 and cp are considered as unkown parameters.
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The advantage of using the step function is that both the cutoﬀ and the predictive
values are parameters of the model. Even in case the assumption of a step function
is strong and the model is misspeciﬁed, the estimates of the assumed step function
are consistent for the parameter values, for which the assumed model minimizes the
distance from the true distribution in terms of Kullback-Leibler divergence (Kullback
and Leibler, 1951); (Huber et al., 1967); (Bunke et al., 1998).
We suggested a mixture prior for the cutoﬀ to acknowledge potential prior-data
conﬂict. One of the components of the mixture prior is an informative precise prior,
i.e. the the true cutoﬀ lies in an interval of high probability, the other component of
the mixture prior is an uninformative prior taking values in the span of the biomarker
measurements. For the predictive values we assumed Uniform distributions on the
unit interval. We run the analysis using MCMC Metropolis-Hastings (Metropolis
et al., 1953); (Hastings, 1970), to approximate the posterior distribution.
Application to survival data - Cox regression
In the contributed paper Vradi et al. (2018), we applied our proposed method to
two real datasets. The ﬁrst set included data on the use of the Prostate Speciﬁc
Antigen as a diagnostic marker for prostate cancer, the second example is concerned
with the time-to-event data where the thickness of the tumor is a marker associated
with increased risk of death from melanoma.
In addition, we introduce an application of our method on survival data. The data
is from a study for a cancer treatment for which a composite biomarker score has
been developed, which is believed to predict the overall survival (OS). To maintain
conﬁdentiality, the study is anonymized. The aim of this analysis is to estimate
a cut-oﬀ value of the composite score such that the patients below and above the
cutoﬀ have a pronounced diﬀerence in their survival probabilities.
In a survival setting, we assume the following: Let T ∗i denote the event time for
subject i, i = 1, ..., n. Due to censoring, instead of observing T ∗i , we observe the
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bivariate vector (Ti,Δi) where Ti = min(T
∗
i , Ci) and Δi =  {T ∗i ≤Ci} with   the
indicator function and Ci is the censoring time. In conclusion, we assume that we
observe the i.i.d. pairs (Ti,Δi) for n individuals. We apply the Cox proportional
hazards model, the most widely used semi-parametric regression model analysis for
survival times. The estimator of β is given by optimizing the partial likelihood for
the Cox model given by:
L(β) =
n∏
i=1
(
eX
T β∑n
l=1 Yl(ti)e
XT β
)Δi
with Yi(t) =  {Ti≥t} denotes the indicator of whether the individual i is at risk at
time t and Y (t) =
∑n
i=1 Yi(t) denotes the total number from the sample that is at
risk at time t and X denotes the vector of covariates for individual i.
Back to our data application, we consider the composite score Xi measured on
i = 1, ..., 499 patients. In order to ﬁt the Cox model for cut-oﬀ estimation, we
assume a dummy variable Z =  {X>cp}. Conditional on the biomarker measurement,
a proportional hazards model is assumed to hold. Speciﬁcally the hazard at time t
for patient i is taken as
h(t, Z) = h0(t)e
βZ =
⎧⎪⎨
⎪⎩
h0(t), if X ≤ cp
h0(t)e
β, if X > cp
where β quantiﬁes the log diﬀerence in the hazards between the two groups of
patients (above and below cp). Assuming a unifrom prior for all the parameters,
results regarding the posterior density of the cutoﬀ and the survival curves for the
patients below and above the estimated cutoﬀ are shown in Figure 3.4. The posterior
median for cp is 1.63 with 95% credible interval (0.39− 2.13) and the log-rank test
(Breslow et al., 1984) results in a p-value equal to 0.006, indicating a signiﬁcant
diﬀerence between the two survival curves for the two group of patients. The hazard
ratio was found to be equal to 1.35 (95% CI, 1.08-1.68), i.e. the patients above the
cutoﬀ are 35% more likely to die than patients below the cutoﬀ value.
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Figure 3.4: Left ﬁgure: Posterior density for the cutoﬀ. The red vertical line rep-
resents the median of the posterior distribution and the dashed vertical
lines the 95% credible intervals. Right ﬁgure: Kaplan Meier plot for the
overall survival of the two groups deﬁned by the estimated cutoﬀ taken
as the posterior median
Conclusion
To summarize, our results suggest that the proposed Bayesian method provides a
practical strategy for cutoﬀ selection and for clinical utility estimation of biomarker
assays. In our simulation study, see Vradi et al. (2018), we have concluded that the
Bayesian 95% credible intervals have good coverage probabilitiy, which are close to
the nominal value both for the cutoﬀ and the predictive values. In our simulations,
we considered diﬀerent prior speciﬁcations, including a very informative, an unin-
formative and mixtures of them. In all cases we obtained satisfactory results, and
especially when precise prior information is available, the parameters were nearly
unbiased with high precision. The Bayesian approach is very tractable in estimating
the distribution of the parameters of interest. Moreover, our results show that point
estimators (e.g. posterior mean) are essentially unbiased in every tested scenario,
prior constellations and sample size assumptions.
An important aspect to consider when using Bayesian inference is that we can
incorporate prior information into the cut-point through the prior distribution. In
our work, we present four diﬀerent prior speciﬁcations, including uninformative,
informative, and mixture priors. In all cases, estimation gives satisfying results and,
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especially when precise prior information is available, the estimated parameters are
nearly unbiased and highly precise. We suggest using a mixture prior, since it works
well in practice and it is robust with respect to potential prior-data conﬂicts.
A possible extension of the proposed method could be to take into account multiple
cutoﬀs, i.e. consider a step function with more than one step to ﬁt the data. Based on
this assumption, we could identify diﬀerent risk groups according to their probability
of response. Of major interest, it would be to consider multiple biomarkers and
investigate how to combine them in a single score. Then using the derived score we
can apply the proposed method for patient classiﬁcation. In the following Chapter
4, we introduce a Bayesian method for biomarker selection and classiﬁcation by
controlling the test’s clinical utility as expressed by the predictive values.
CHAPTER 4
A Bayesian method for variable selection and classiﬁcation
under constrained clinical utility
Contributed material
Vradi E, Jaki T, Vonk R, Brannath W(2018). Bayesian variable selection and clas-
siﬁcation with control of predictive values. Manuscript submitted.
In Chapter 4, we bring together two topics: one is the idea of variable selection and
the other is the topic of cutoﬀ estimation for classifying patients according to their
response probability. This work is motivated by the important task of selecting a
set of predictive biomarkers (discussed in the ﬁrst chapter), derive a risk score out
of the selected markers and subsequently estimate a cutoﬀ value (discussed in the
second chapter), that will be used as a criterion for distinguishing two groups of
patients, e.g. the classiﬁcation of patients in resonders and non-responders’ groups.
In this chapter we propose a method for combining the two ideas using Bayesian
methodology. This leads to a method to select variables for patient classiﬁcation,
taking the desired clinical utitily into account already at the selection stage of the
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process.
Preliminaries in Bayesian variable selection
In the Bayesian setting, the model selection problem is transformed into the form of
parameter estimation. Bayesian variable selection procedures are more informative
than penalization methods, because they automatically address the model selection
uncertainty. Rather than searching for a single optimal model, Bayesian analysis
provides estimates of the posterior probability of all models within the considered
class of models. From a Bayesian perspective, variable selection is performed by
imposing prior distributions on the regression coeﬃcients. There are two main
alternatives for the choice of the prior: two component discrete mixture priors and
a variety of continous shrinkage priors.
For the ﬁrst approach, known as the Spike-and-Slab and suggested by Mitchell and
Beauchamp (1988), assumes that the prior distribution for each regression coeﬃcient
βj is a mixture of a point mass at zero (βj = 0) and a diﬀuse uniform distribution
elsewhere. George and McCulloch (1993) propose a stochastic seach variable selec-
tion (SSVS) where the subset selection is derived from a hierarchical normal mixture
model. The Spike-and-Slab prior is equivalent to Bayesian Model Averaging (BMA)
over the variable combinations and often has good performance in practice. One
drawback is that the results can be sensitive to prior choices of the slab components
or to prior inclusion probability. Moreover, inference with BMA can be computa-
tionally demanding with a large number of variables, due to the huge model space
search.
Continuous shrinkage priors on the other hand, place absolutely continous distribu-
tions on the entire parameter vector to yield a sparse estimator. Within the class of
shrinkage priors, scale mixtures of normals and normal-gamma distributions for the
coeﬃcients β have received extensive attention (Andrews and Mallows (1974), West
(1987)) and more recently by Fernandez and Steel (2000), Griﬃn et al. (2010), Grif-
ﬁn and Brown (2012), Liang et al. (2008) and the references therein. Carvalho et al.
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(2009) and Polson and Scott (2010) introduced the global-local shrinkage priors that
adjust for sparsity via the global shrinkage and identify signals by local shrinkage
parameters.
The Bayesian lasso (Park and Casella, 2008; Hans, 2009) typically refers to
the use of double-exponential shrinkage prior for the regression coeﬃcients β in the
normal linear regression model y = Xβ where y is the n−vector of observations
and X is a n × d vector of predictor variables. The regressions coeﬃcients are
distributed as β ∼ DE(0, 1/λ). The posterior mode under the double-exponential
prior is equivalent to the frequentist Lasso estimate by Tibshirani (1996).
The horseshoe prior (HS), that belongs to the family of global-local shrinkage
priors, was introduced by Carvalho et al. (2010). It refers to a hierarchical-shrinkage
prior for the regression coeﬃcients where their standard deviation is the product of
a local (λj) and global (τ) scaling parameter. It is given by
βj|λj, τ ∼ Normal(0, λ2jτ 2)
λj ∼ Cauchy+(0, 1) and τ ∼ Cauchy+(0, 1)
where the Cauchy+(0, 1) is a standard half Cauchy distribution on the positive reals
with location parameter 0 and scale 1. The intuition behind the horseshoe prior
according to Piironen and Vehtari (2016) is the following: the global parameter τ
pulls all the weights (βj) globally towards zero, i.e. estimate the overall sparsity,
while the thick half-Cauchy tails for the local shrinkage parameter λj allow some
of the weights to escape shrinkage, i.e. is able to ﬂag the non-zero elements of β.
Diﬀerent levels of sparsity are based on the value of τ , i.e. when τ → 0 will shrink
all βj to zero, whereas with large τ there is very little shrinkage towards zero. The
advantage of the HS is that it is shown to be robust at handling unknown sparsity
and large outlying signals.
Although the choice of independent half standard Cauchy priors for all λj is less
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debated, the choice for the prior on τ has raised discussions (see (Piironen and Ve-
htari, 2016)). For example, it is recommented to use τ ∼ C+(0, α2), where C+(0, α2)
denotes the half-Cauchy distribution with location 0 and scale α and the authors
provide some suggestions on the choice of α. Van Der Pas et al. (2014) and Pi-
ironen and Vehtari (2016) discussed an intuitive way to design a prior for τ based
on assumptions about the number of nonzero elements in the vector β. Theoretical
justiﬁcation why it is a desirable choice the half-Cauchy prior for scale parameters
in hierarchical models is given in Gelman et al. (2006) and Polson et al. (2012).
Spike and Slab prior (SpSl) is a popular prior for sparse Bayesian estimation
and refer to the prior of β written as a two-component mixture of priors. There are
two diﬀerent speciﬁcations for the spike component: spikes speciﬁed by an absolutely
continous distribution and spikes deﬁned by a point mass at zero, the so called Dirac
spike. The slab component has its mass spread over a wide range of plausible values
for the regression coeﬃcients. The spike and slab prior is speciﬁed as p(βj) =
(1 − γj)pspike(βj) + γjpslab(βj). A detailed overview regarding diﬀerent spike-and-
slab priors as well as comparisons amongst them can be found in Malsiner-Walli
and Wagner (2011). However, the authors conclude that spike-and-slab priors do
not discriminate between variables with zero and weak eﬀects. The choice of a
smaller variance for the slab component will not solve the problem but it will cause
an increase in the posterior inclusion probabilities of all eﬀects, even for the zero
eﬀects.
An absolutely continuous spike is in principle speciﬁed by any unimodal continuous
distribution with mode at zero. Here we consider the prior for βj as a spike taken
to be a delta spike (Dirac spike) at the origin δ0 combined with a normal slab. The
prior inclusion probability is γj ∼ Bernoulli(π) and the prior for βj is written as
βj|γj, σ ∼ (1− γj)δ0 + γjNormal(0, σ2)
σ2 ∼ Inv −Gamma(as, bs)
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Gibbs sampling (Geman and Geman, 1984; Gelfand and Smith, 1990; Casella
and George, 1992) is a sampling algorithm based on Markov Chain Monte Carlo
(MCMC) techniques. In Bayesian inference, MCMC methods are used for obtaining
a sequence of samples that can be used to approximate the posterior joint dis-
tribution of the parameters. Gibbs sampling is a method for sampling from the
conditional densities of the parameters and is particularly well-suited to Bayesian
networks (express the conditional dependence structure between random variables)
which are typically speciﬁed as a collection of conditional distributions. The theory
of MCMC guarantees that the stationary distribution of the samples (discarding the
initial burnin samples) generated under Gibbs algorithm is the target joint posterior
that we are interested in (Gilks et al., 1996).
Bayesian Variable Selection and Thresholding
From a Bayesian perspective, the variable selection property is ad hoc. Suppose
there are d covariates which are candidates for inclusion in the model. Then each
model m ∈ M can be naturally represented by a d−vector γ of binary indicator
variables determining whether or not a covariate is included in the model. Let γ be
the d−vector where γj = 1 if the predictor variable Xj is included in the model and
γj = 0 otherwise.
Under the continuous prior distribution, the probability of the event {βj = 0} is
zero. In order to make posterior inferences about events such as {βj = 0} prior
probability mass must be allocated to these events. In the Bayesian setting, placing
prior mass on the events {βj = 1} is equivalent to assigning a prior distribution
to the space of regression models that are to be considered. If π(m) is the prior
probability of model m, the posterior probability of the regression model is
π(m|y) = π(y|m)π(m)∑
m∈M π(y|m)π(m)
whereM is the collection of all possible models and π(y|m) is the marginal likelihood
of the observed data y under model m. A review of Bayesian variable selection
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methods for diﬀerent prior considerations and thresholding procedures has been
thoroughly discusssed in O’Hara et al. (2009).
Kuo and Mallick (1998) considered an approach for variable selection where they
proposed a prior distribution π(β) that is independent of γ (and therefore from
model M) so that π(β|β\j, γ) = π(β|β\j), where β\j denotes all terms of β except
βj. The advantage of this approach is that implementation is straitforward and
requires only the speciﬁcation of the prior for β. The full conditional posterior
distribution is given by:
π(βj|y, γ, β\j) ∝
⎧⎨
⎩ π(y|γ, β)π(βj|β\j) , γ = 1π(βj|β\j) , γ = 0
According to their proposal, the linear predictor for the generalized linear model
determined by γ may be written by
η =
d∑
j=1
γjXjβj (4.1)
The selection on the important predictors is done by examining the marginal poste-
rior inclusion probabilities π(γj = 1|y). In practice the most important variables are
identiﬁed by their frequence of appearance in the Gibbs samplers. If selection of one
model for prediction is desired, Barbieri et al. (2004) showed (by a mathematical
proof) that the Median Probability model (denoted as MP), deﬁned to be the model
containing all variables with
π(γj = 1|y) ≥ 1/2 (4.2)
is the best model with regard to predictive performance. Another approach to iden-
tify non-important covariates can be based on posterior credible intervals, where
selection of predictors is done by checking whether zero is included in the coeﬃ-
cients’ credible interval or not (van der Pas et al., 2017; Li et al., 2010). The latter
method has a poor performance in high dimensional settings and does not quantify
the importance of each covariate (i.e. as inclusion probablities do). It is worth men-
tioning that the MP model suggested by Barbieri et al. (2004) assumes orthogonal
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predictors, an assumption that is rarely apply in practice. Moreover, the MP model
was derived assuming Gaussian noise and the theory was not applied to classiﬁcation
problems. However, Piironen and Vehtari (2017) applied the MP model on classiﬁ-
cation data with correlated predictors and showed through numerical experiments
that the MP model performs well in terms of correct variable selection as well as
predictive performance of the model.
When an absolutely continuous prior is used, the inclusion indicators are sampled
conditionally on βj. For the horseshoe prior, Carvalho et al. (2010) suggested that
variable selection is done based on the posterior mean
E(βj|y) = (1− E(κi|yi))yi
where κi =
1
(1+λ2jτ
2)
is the shrinkage factor which describes how much coeﬃcient βj
is shrunked towards zero. Carvalho et al. (2010) interpreted the shrinkage factor
as inclusion probabilities by thresholding 1 − κj ≥ 0.5. According to Carvalho
et al. (2010); Scott and Berger (2006) this thresholding approach induces a multiple
testing rule, i.e. reject the null hypothesis βj = 0 if 1 − κj ≥ 0.5, that controls
the rate of type I error. The Spike-and-Slab prior with a dirac spike is modeling
the inclusion probability directly and therefore variable selection is based on the
marginal posterior of γj.
Bayesian variable selection and cutoﬀ estimation with constrain on PPV
In some diagnostic situations it is essential to include the control of classiﬁcation
measures or most importantly, as we emphasized also in Chapter 3, the control of
the clinical utility of the test. In this contributed paper, we are interested in the
selection of the markers for a risk score, which lead to a prespeciﬁed lower bound of
admissible values for PPV. For example, keep the biomarkers which, when combined,
lead to a PPV greater or equal than 90%.
It is common that the evaluation of the clinical utility is done after the selection
of a subset of biomarkers. That means that the important information requiring a
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high PPV value is not considered in the optimization procedure and therefore the
computed PPV is not necessarily satysfying the constraint. Here we aim to include
the predictive values in the optimization algorithm. We used a step function to
model the probability of response as proposed in Chapter 3. Therefore the predictive
values (PPV and 1-NPV) and the cutoﬀ cp are parameters of the model and the
Bayesian methodology can be easily applied. The application of the step function in
a setting with multiple predictors can be easily done by assuming a combined score,
or a risk score, of the selected biomarkers (instead of a single marker as in Chapter
3).
Our aim is the classiﬁcation of patients as well as identiﬁcation of the important
variables characterizing the diﬀerent response groups. We achieve both goals simul-
taneously by combining the proposed step function model (for estimating the cutoﬀ
value) to discriminate and classify patients with Bayesian variable selection methods
for the identiﬁcation of important predictors. The modeling is done under the con-
straint that the selected variables provide a classiﬁer with high positive (or negative)
predictive value. In the Bayesian setting, the constrain that the PPV belongs to a
predetermined interval of high values, i.e. (90% − 100%), is achieved through the
prior distributions on the predictive values. For example, using a shrinkage prior
for β and the linear predictor as in equation (4.1), the probability of response is
modeled as
p = P (y = 1|βX) =
⎧⎨
⎩ p1 = P (y = 1|βX ≤ cp)p2 = P (y = 1|βX > cp)
The prior F for the coeﬃcients β can be taken as one of the priors proposed in
this chapter and the parameters cp, p1 and p2 are assumed to follow a Uniform
distribution, where l is the lower bound of the constraint on the positive predictive
value.
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β ∼ F
cp ∼ Uniform(a, b)
p1 ∼ Unif(0, p2) and p2 ∼ Unif(l, 1)
(4.3)
The estimation of the cutoﬀ on the risk score is done in two steps. Since
the selection of biomarkers in a Bayesian model is ad hoc, the estimation of the
parameters of the step function should be done accordingly in two steps. We are
interested in the conditional distribution of the risk score for the ﬁnally selected
biomarkers. Therefore, by ﬁtting the model in (4.3) we obtain the marginal posterior
density for the cutoﬀ but not conditionally on the selected biomarkers. By ﬁtting
the model assuming the step function at the ﬁrst step, we derive a vector of the
estimated eﬀects βˆ, i.e. the posterior means of the βj. To obtain the conditional
distribution of the cutoﬀ, we ﬁt the model with the step function but now for ﬁxed
βˆ and data (X, y). This second step in our estimation procedure can be seen as an
empirical Bayes approximation.
Step 1 : In the ﬁrst step we ﬁt a Bayesian model with a shrinkage prior and ap-
proximate the posterior distribution
f(β, cp, p1, p2, θ|X, y) ∝ L(β, cp, p1, p2|X, y)× f(cp)× f(p1)× f(p2)× f(β|θ)
where f(·) denotes the density function, L is the likelihood function and θ denotes
the hyperparameters in the model (θ will be diﬀerent for the diﬀerent priors for
β). The selection of the variables that are included in the ﬁnal model is based on
the thresholding criterion in (4.2), i.e. keep those βj that the marginal inclusion
probability is greater than 1/2. We take as point estimates the posterior means of
the selected βj and calculate the estimated risk score as βˆX.
Step 2 : Fit the model in (4.3) now for ﬁxed βˆ and approximate the posterior den-
sity f(cp, p1, p2|X, y, βˆ) implementing the Gibbs sampling approach. The estimated
cutoﬀ and predictive values are taken as posterior means of the marginal posterior
distributions for each of the parameter.
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Conclusion
We propose a Bayesian method that simultaneously performs variable selection as-
suming a shrinkage or mixture prior (Laplace, Spike-and-Slab and Horseshoe), and
cutoﬀ estimation under the constraint that the PPV belongs to a prespeciﬁed in-
terval of plausible values. The optimization with the constraint provides the best
classiﬁer with a PPV in the prespeciﬁed interval.
In the simulation study we conducted (see the contributed paper), we used the
Laplace, the SpSl and the HS priors and evaluated their performance in terms of
correct variables included in the model as well as in terms of classiﬁcation perfor-
mance. We constrained p2 to have a lower bound of 0.8, i.e we used a Uniform
distribution in the interval (0.8,1). We found that the True Positives (TP), deﬁned
as the number of times in the simulation runs that the important variables were
selected in the model was at least 70%. The False Positives (FP), deﬁned as the
average number that a non-important variable was included in the ﬁnal model, did
not exceed 20% on average.
We compared our poposed method with the two-stage approach, described as follows;
the algorithm ﬁrstly does variable selection assuming a logistic model and at the
second stage, considering the variables selected from stage one, estimates the cutoﬀ
and predictive values by ﬁtting the step function model. The proposed method
diﬀers from the two-stage appoach at the ﬁrst stage, where we ﬁt a step function
instead of a logistic. By considering the step function at the ﬁrst stage, we are able
to include information about the cutoﬀ and predictive values already at the selection
stage.
The classiﬁcation performance of the proposed method was assessed by calculating
the Brier score (Brier, 1950) as well as the bias of the predictive values on a testing
(validation) dataset. Regarding the classiﬁcation error, the HS prior resulted in
slightly higher errors for the proposed approach compared to the Laplace ans SpSl
priors. We observed the higher error in the scenario where the predictors are highly
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correlated.
Regarding bias, the proposed approach behaved similarly to the two-stage procedure
for all the priors, resulting in nearly unbiased estimators for the predictive values.
We showed that the bias of p1 was on average close to zero for all the diﬀerent priors,
and was found slightly higher for p2 which was on average about 10%. We observed
a tendency to slightly overestimate p1 and underestimate p2. When the correlation
among predictors is high (i.e. > 0.5), the bias of p2 was slightly higher than in other
scenarios, and on average 17%.
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ABSTRACT
The growing role of targeted medicine has led to an increased focus on the
development of actionable biomarkers. Current penalized selection methods
that are used to identify biomarker panels for classification in high-dimensional
data, however, often result in highly complex panels that need careful pruning
for practical use. In the framework of regularizationmethods, a penalty that is a
weighted sum of the L1 and L0 norm has been proposed to account for the
complexity of the resulting model. In practice, the limitation of this penalty is
that the objective function is non-convex, non-smooth, the optimization
is computationally intensive and the application to high-dimensional settings
is challenging. In this paper, we propose a stepwise forward variable selection
method which combines the L0 with L1 or L2 norms. The penalized likelihood
criterion that is used in the stepwise selection procedure results in more
parsimonious models, keeping only the most relevant features. Simulation
results and a real application show that our approach exhibits a comparable
performance with common selection methods with respect to the prediction
performance while minimizing the number of variables in the selected model
resulting in a more parsimonious model as desired.
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Introduction
The high costs and long duration of clinical development, paired with high levels of attrition, require
the quantification of the risk when moving from early to late stage clinical development, and
biomarkers may play an important role in this quantification. However, only rarely the number of
variables (biomarkers) in the resulting panel plays an active role in selection procedures. Variable
selection is an important aspect in the determination of such panels in the framework of high-
dimensional statistical modeling. In practice, a large number of candidate predictors are available for
modeling. Keeping only the relevant variables in the model enhances the interpretation and may
increase the predictability of the resulting model.
Particularly in the framework of regularization methods, various penalty functions are used to perform
variable selection. Frank and Friedman (1993) proposed the bridge regression by introducing the penalty
of the form Lq ¼
Pd
j¼1
βj
 q; q> 0, for the vector of regression coefficients β ¼ β1; β2; . . . ; βd  2 Rd.
When q  1 the penalty performs variable selection. The case where q ¼ 1 is the L1 penalty and
corresponds to the Least Absolute Shrinkage and Selection Operator (Lasso) (Tibshirani, 1995 ). It
performs continuous shrinkage and variable selection at the same time, whereas for q ¼ 2 we get the
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ridge estimator (Hoerl and Kennard, 1970) that shrinks coefficients toward zero but it does not perform
variable selection. The limit of the Lq as q ! 0 gives the L0 penalty, which penalizes the number of non-
zero coefficients and thus is appealing formodel selection, if sparsemodels are of advantage. However, due
to its non-convexity and discontinuity at the origin, the corresponding optimization problem becomes
difficult to implement in high dimensions.
In genomic research, an L1 penalty is routinely used due to its convexity and optimization
simplicity. However, the result of the L1 type regularization may not be sparse enough for a good
interpretation. The development of methods to obtain sparser solutions than through L1 penaliza-
tion methods is becoming essential part in the classification and feature selection area. A variable
selection method that combines the L1 and L0 penalties was proposed by Liu and Wu (Liu and Wu,
2007). They used a mixed integer programming algorithm for optimization of the objective function.
The results showed that their method achieved sparser solutions than Lasso and more stable
solutions that the L0 regularization. However, the application was limited to moderate data sizes,
due to computational inefficiency for large-scale problems. Other combinations of Lq penalties have
been proposed so far (Zou and Hastie, 2005) and recently (Huang et al., 2016) with each of these
methods using a different optimization algorithm to approach the solution.
In this article, we propose a method for variable selection that penalizes the likelihood function with a
linear combination of L0 with L1 or L2 penalties (CL, CL2) in a stepwise forward variable selection
procedure. The aim is to obtain a model that is sparser than the model with the L1 penalty alone and at
the same time achieve a good predictive performance. Moreover, a strong motivation for the proposed
stepwise forward variable selection method is that state-of-the-art global optimization algorithms for non-
smooth and non-convex functions do not provide satisfactory results. In Section 2, we define the CL and
CL2 penalties and present the algorithm for solving the penalized logistic regression problem with these
combined penalties. In Section 3, we use simulated data to evaluate the performance of ourmethod, andwe
compare it to Lasso and adaptive Lasso both in terms of correct variable selection (true covariates with
βj0) as well as predictive performance. Finally, we show an application of our method for classification
and variable selection on a real dataset with proteinmeasurements to identify the least number of predictors
that can best classify responders and non-responders to a treatment.
Methods
Regularization
Suppose we have data (X, y), where y ¼ y1; y2; . . . ; ynð Þ is the vector of responses and X is an n d
matrix of predictors. We will assume that the observations are independent and the predictors standar-
dized. With linear predictor η ¼ XTβ and link function g the generalized linear model is expressed as
gðEðyjXÞÞ ¼ η (2:1)
Under the regularization framework, the estimated coefficients β^ ¼ β^1; β^2; . . . ; β^d
 
2 Rd are
obtained by minimizing the objective function  logLþ λP βð Þ, and are given by:
β^ ¼ argmin
β
logLþ λP βð Þf g
where P βð Þ is a regularization term. The parameter λ > 0 is a tuning parameter and  logL is the
negative log-likelihood. One of the most popular and commonly used regularization method is the
L1 regularization (Lasso), where P βð Þ ¼
Pd
j¼1
βj
 . Setting λ ¼ 0 reverses the Lasso to maximum like-
lihood estimation. On the other hand, a very large λ will completely shrink β to zero thus leading to
the empty or null model. In general, moderate values of λ will cause shrinkage of the solutions
toward zero, and some coefficients may be exactly zero.
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Other types of L1 regularization include the adaptive Lasso, where adaptive weights are used for
penalizing different coefficients in the L1 penalty and which was shown to have the oracle property
(Zou, 2006). A variable selection and estimation procedure is said to have the oracle property i) if it selects
the true model with probability tending to 1 and ii) if the estimated penalized coefficients are asympto-
tically normal, with the same asymptotic empirical variance as the estimator based on the true model.
However, the L1 type regularization is consistent only under rather restrictive assumptions (Zhao
and Yu, 2006) and the coefficient estimates are severely biased due to shrinkage (Meinshausen and
Yu, 2009; Fan and Li, 2001). Although the L0 norm, where P βð Þ ¼
Pd
j¼1
1βj0 and 1βj0 is the indicator
function of whether βj0, tend to yield the sparsest solutions, its implementation in high-dimen-
sional data becomes an NP hard optimization problem and is not computationally feasible. Classical
information criteria like AIC (Akaike, 1974) or BIC (Schwarz, 1978) lie in the general class of the
regularization λP βð Þ ¼ λ Pd
j¼1
1βj0 for suitable choices of λ. In order to gain a more concise and
sparse solution and while keeping a high predictive accuracy of the classification model, we propose
a regularization term that combines the L0 with L1 or L2 norms (Liu and Wu, 2007). Figure 1 plots
Figure 1. Plot of the L0; L0 ε; L2; L1 norms with ε ¼ 0:1andd ¼ 1
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the penalty functions L1 and L2 in the bottom panel and the L0 penalty in the top panel. Unlike L2 ,
the penalty terms L1 and L0 are singular at the origin and thus perform variable selection (Fan and
Li, 2001).
The combined L0 þ L1 penalty
Following Liu and Wu (Liu and Wu, 2007) the penalization term is defined
as CLαε βð Þ ¼ 1 að ÞL0ε þ aL1 , where 0  a  1 is a weighting parameter between L0ε and
L1 penalties, with L0ε given by:
L0
ε βð Þ ¼ 1; βj j  εβj j
ε ; βj j< ε

(2:2)
Clearly CL1ε ¼ L1 (a ¼ 1) and CL0ε ¼ L0ε a ¼ 0ð Þ are special cases of CLαε. Discontinuity at the
origin of L0 makes the optimization difficult, and therefore we consider the continuous approxima-
tion to L0 defined by (2.2). The limit of L0ε βð Þ when ε ! 0 is L0 βð Þ itself. When ε > 0 is small,
L0ε βð Þ is a good approximation to L0 βð Þ (Figure 1 top right). The estimated coefficients are obtained
by minimizing the objective function
 logLþ λ
Xd
j¼1
CLα
ε βj
 
(2:3)
and are given by
β^CLαε ¼ argmin
β
logLþ λ
Xd
j¼1
CLα
ε βj
 ( )
:
The combined L0 þ L2 penalty
We now consider another combination, the L0 norm with L2 . The motivation for combining
the L0 norm with L2 , is to consider a penalty that will join the nice properties of the L2 and
those of the L0 norm, which is to perform variable selection L0ð Þ and keep in the model groups
of variables that are correlated ðL2 Þ. In theory, a strictly convex function provides a sufficient
condition for such grouping of variables and the L2 penalty guarantees strict convexity. The
grouping effect refers to the simultaneous inclusion (or exclusion) of correlated predictors in
the model.
The penalization term is now defined CL2αε βð Þ ¼ 1 að Þ L0ε þ a L2 , where 0  a  1. The L0ε
term introduced above is for variable selection and the L2 penalty shrinks the coefficients toward
zero with no contribution to variable selection. Figure 2 gives a graphical representation of the
regularization terms CL0:30:1, L1, L2, CL20:50:1.
The stepwise forward procedure
In their paper, Liu and Wu (2007) proposed a global algorithm to solve the corresponding
difficult non-convex problem (mixed integer linear programming). However, the applicability
was restricted to moderate datasizes. As mentioned by Frommlet F. and Nuel G. (Frommlet and
Nuel, 2016), when the number of predictors grows large (d > 20) it is not possible to apply
algorithms which guarantee to find the optimal solution (Furnival and Wilson, 1974) and
instead heuristic search strategies like stepwise procedures may be considered. By using
heuristic techniques, we can approximate the solution of the non-smooth, non-convex, and
738 E. VRADI ET AL.
NP-hard optimization problems like the one in equation (2.3), where exact algorithms are not
applicable for such minimization problems.
The optimization of the objective function (2.3) is rather challenging since CLαε βð Þ and
CL2αε βð Þ are non-convex and non-differentiable at some points of the parameters’ space. We
apply the Broyden (1970), Fletcher (1970), Goldfarb (1970), and Shanno (1970) (BFGS) variable
metric (quasi-Newton) method, which is shown to work well for the optimization of non-smooth
and non-convex functions (Lewis and Overton, 2009 ; Lewis and Overton, 2013; Curtis and Que,
2015 ). The BFGS method uses an approximation of the Hessian matrix to find the stationary points
of the function to be minimized. Its ability to capture the curvature information of the considered
function renders the method so effective.
We propose to use a stepwise forward variable selection using the previously introduced penalized
likelihood criterion for feature selection that can be used effectively in high-dimensional data. In this
stepwise forward selection framework, at each step we optimize the objective function  logLþ
λ a L1 using the BFGS algorithm and obtain
β^L1 ¼ argmin
β
logLþ λ a
Xd
j¼1
L1 βj
 ( )
:
The selected model is based on the criterion that minimizes the value of
 logL β^L1
 
þ λaL1 β^L1
 
þ λ 1 að Þ L0 β^L1
 
(2:4)
The suggested algorithm is described as follows:
Figure 2. Two dimensional contour plot for the regularization terms CL0:30:1; L1; L2; CL20:50:1 with ε ¼ 0:1andd ¼ 2: The black
dashed curve represent the CL penalty (α ¼ 0:3; ε ¼ 0:1) and the green shaped curve is the contour of the CL2 (α ¼ 0:5; ε ¼ 0:1).
The outer contour shows the shape of the ridge penalty, while the blue solid line is the Lasso penalty.
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Step 1
● Given a set of d standardized predictors X1;X2; . . . ;Xd and a response yi 2 0; 1f g; i ¼ 1; . . . n
we consider all possible univariate models (M1;M2; . . . ; Md)
M1 : Y, β0 þ β1X1, . . . M2 : Y, β0 þ β2X2, . . . M3 : Y, β0 þ β3X3, . . ., Md : Y, β0 þ βdXd
● Estimate β^L1
M1
; . . . ; β^L1
Md
and keep Mj, j 2 1; . . . ; df g that gives the smallest value of the function
(2.4), e.g. keep variable X2
Step 2
● With the model chosen in step 1 (e.g. M2) and in an additive way we consider all the d  1
models (M0) by adding the remaining d 1 variables one at a time to the model M2.
M01 : Y, β0 þ β2X2 þ β1X1
M02 : Y, β0 þ β2X2 þ β3X3
..
.
M0d : Y, β0 þ β2X2 þ βdXd
● Keep the model that minimizes the function in (2.4),
Step 3
● Continue adding single variables until the value of the function (2.4) in the current step is
bigger than its value in the previous step.
The advantage of using the function (2.4) instead of (2.3) in the optimization is that we no longer
need to consider the continuous approximations to the discontinuous L0 function and therefore we
eliminate the number of parameters by the continuity parameter ε. The reason why we can do so is
that within each step the L0-penality term remains constant (since the dimension of the model is
fixed) and hence play no role in the determination of the regression coefficients. The L0-penality
term only plays a role for the stopping criterium.
Sparse logistic regression with combined penalties
As a particular example, we consider the binary linear regression model (2.1), where y 2 0; 1f g, is a
vector of n observed binary outcomes, β ¼ β1; β2; . . . ; βd
  2 Rd is the vector of coefficients. The
link function is the logit function logit pð Þ ¼ log p1p
 
, where p is the conditional event probability
and is given by
p ¼ P y ¼ 1jXð Þ ¼ e
η
1þ eη (2:5)
The coefficient estimates are obtained by minimizing (2.3) with the log-likelihood
logL ¼ L βjy;Xð Þ ¼
Xn
i¼1
yi log pið Þ þ 1 yið Þlog 1 pið Þ
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Results
In this section, we examine via simulations the performance of logistic regression when models are
selected and estimated with the above introduced combined penalties (CL, CL2) by either stepwise
forward selection as introduced in Section 2 (stepCL and stepCL2) or by global minimization (CL,
CL2). In the stepwise model selection scheme, we also examine the performance of the stepwise
adaptive L1 model with the λ 1 að Þ L0 selection criterion (stepAdaCL). For that model, the
objective function to minimize is  logLþ λ a Pd
j¼1
wjL1 βj
 
, where wj ¼ 1βjj jγ are the adaptive
weights and βj

  is the ridge regression estimator. The estimation is done with the stepwise
algorithm described in Section 2.4.
Although the proposed method is a stepwise variable selection procedure, we did not consider the
comparison with other stepwise methods like the stepwise BIC or AIC, as they tend to perform
poorly when the dimension is large relative to the sample size and are usually too liberal, that is, they
tend to select a model with many spurious covariates (Chen and Chen, 2008 ). As mentioned by
Zhang and Shen (Zhang and Shen, 2010) these criteria may be inadequate due to their nonadaptivity
to the model space and infeasibility of exhaustive search.
We include the global minimization in spite of the disadvantages mentioned in Section 2 for a
comparison. We also consider the results from Lasso (L1 penalty) and the adaptive Lasso. We compare
the different methods in terms of the fraction of correctly selected variables and the prediction
classification accuracy. The real data come from a biomarker study of protein measurements with the
objective to select biomarkers that potentially discriminate between responders and non-responders.
Simulation study
We simulate data for varying number of predictors. We consider two settings, one high-dimensional
data where the number of predictors (d) exceeds the number of samples (n), and a setting where the
sample size is smaller than the dimensionality of the data. We assume multivariate normal predictors
X1; . . . ; Xd with pairwise correlation ρ (compound symmetry). Let ρ denote the correlation between
variables Xm; Xl where m; l 2 1; . . . ; df g, ml.
The true model that was used to generate the outcome has k informative covariates
Xk; k 2 Z; 1< k< d. We consider a classification problem with y a binary response and standard
normally distributed predictors X,MVN 0;Σð Þ, where Σ is the covariance matrix. We consider the
logistic model with logit link function, logit pð Þ ¼ XTβ, as described above with p the probability of
y = 1 given X as defined in (2.5). In other words, each component of the response vector y is viewed
as a realization of a Bernoulli random variable with probability of success p.
Four scenarios will be presented here, each with n = 100 samples.
1. Scenario 1: d ≤ n, correlation ρ ¼ 0:5.
We consider d = 50 covariates, with k = 3 informative predictors and coefficient vector
β ¼ 3; 1:5; 2; 0; . . . ; 0|ﬄﬄﬄ{zﬄﬄﬄ}
47
0@ 1A. The correlation between the three informative predictors is
ρ ¼ corr Xm;Xlð Þ ¼ 0:5, ml and m; l ¼ 1; 2; 3.
2. Scenario 2: High-dimensional setting d ≥ n, correlation ρ ¼ 0:5
We consider d = 150 covariates, with k = 15 informative predictors with
β ¼ 3; . . .|ﬄ{zﬄ}
3
; 3:5; . . .|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
3
; 1:5; . . .|ﬄﬄﬄ{zﬄﬄﬄ}
3
; 5; . . .|ﬄ{zﬄ}
4
;2; ::|ﬄ{zﬄ}
2
; 0; . . . ; 0|ﬄﬄﬄ{zﬄﬄﬄ}
135
0@ 1A. The correlation ρ between the 15 informa-
tive predictors is corr Xm; Xlð Þ ¼ 0:5; ml and m; l ¼ 1; . . . ; 15.
3. Scenario 3: High-dimensional setting d ≥ n, correlation ρ ¼ 0:7.
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The dataset consists of n = 100 samples and d = 200 covariates, with k = 15 informative predictors
with β ¼ 2; . . .|ﬄ{zﬄ}
4
; 3; . . .|ﬄﬄﬄ{zﬄﬄﬄ}
3
; 1:5; . . . ;|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
4
2; . . . ;|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
3
0; . . . ; 0|ﬄﬄﬄ{zﬄﬄﬄ}
185
0@ 1A. The correlation ρ between the 15 informative
predictors is corr Xm; Xlð Þ ¼ 0:7; ml and m; l ¼ 1; . . . ; 15.
4. Scenario 4: High-dimensional setting d ≥ n, block correlation.
We consider d = 200 covariates, with k = 16 informative predictors with
β ¼ 1; 4; . . .|ﬄ{zﬄ}
4
; 3; . . .|ﬄﬄﬄ{zﬄﬄﬄ}
3
; 1:5; . . . ;|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
4
2; . . . ;|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
4
0; . . . ; 0|ﬄﬄﬄ{zﬄﬄﬄ}
185
0@ 1A. In this scenario, there are two groups (blocks)
of correlated predictors and one single independent feature. The coefficients of d–k = 184 variables
were set to zero, βr ¼ 0; r ¼ 184; . . . ; 200. The correlation between predictors in block 1 is corr
(Xm; XlÞ ¼ 0:4; ml and m; l ¼ 1; . . . ; 7 and the correlation among predictors in block 2 is
corr(Xm; XlÞ ¼ 0:7; ml and m; l ¼ 8; . . . ; 16:
Tuning of parameters
All analyses were done in R version 3.2.3 (R Core Team, 2015). For the Lasso and adaptive Lasso, the
glmnet library was used and all the functions that were used for the combined penalty approach can
be found in the R-package “stepPenal”, available on the CRAN. For the adaptive lasso, weights were
estimated by ridge regression and then used for a weighted L1 penality in estimation of β. The
optimal regularization parameters for the methods stepCL, stepAdaCL, CL, CL2, stepCL2 were tuned
by 10-fold cross-validation on the two-dimensional surface (a; λÞ using a grid of values. The choice
of the optimal parameters was done in the following way. For each configuration of (a; λÞ in the grid,
the AUC of the ROC curves on the validation set was computed in each of the 10 validation sets. The
average of the 10 AUCs was reported together with its standard deviation.
Selection of (a; λÞ was based on the interval A ¼ maxAUC  sdAUC; maxAUC½ Þ where maxAUC
is the maximum average AUC and sdAUC is the standard deviation of the AUCs corresponding to
the (a; λÞ with maximum average AUC. The (a; λÞ that corresponds to the median of the AUCs in
the interval A was chosen for the final model fitting. In case that more than one configurations yields
the median of the AUCs, we select the configuration with the largest λ and smallest a, to obtain the
sparsest model. The use of the interval A acknowledges the sample variability and the fact that we are
aiming for a compromise between good classification performance and complexity of the model. In
other words, a small decrease in the AUC of the ROC curve is acceptable in return to a less complex
model. The Lasso and adaptive Lasso were also tuned by 10-fold cross-validation on the one-
dimensional space (λÞ, using the default settings in R in the function cv.glmnet and the measure
type “auc“.
Simulation results
The different classifiers were built by the estimated tuning parameters on the training set. Then, the
obtained classifiers were applied to the testing set for classification and prediction. For the testing set,
we simulated data from the same distribution as the training set for n = 1000 samples. We simulated
1000 datasets on which we applied all methods. For each method, we computed the mean classifica-
tion performance of the models on the testing sets measured by the AUC of the ROC curve (test
AUC). This is a measure for the discrimination ability of the model to correctly distinguish the two
classes of the response. The complexity of the resulting model was measured by the ratio of correctly
selected variables (true covariates with βj0) to the total variables selected by the model. We will call
this ratio RCV for the rest of the paper.
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This ratio takes values between zero and one. When the model selects none of the informative
variables it is zero and it becomes one, when the selected model includes only the k informative
covariates. The closer the RCV is to one, the sparser the model is and the more it selects the true
variables. The results in Table 1 summarize the performance of the different methods in terms of
model complexity. An ideal model selection method would only select the k true features and set the
coefficients of the other d-k variables equal to zero.
In most of the scenarios, the stepCL and stepCL2 methods yield a higher RCV than the other
methods and on average the stepCL and stepCL2 models are sparser than the other methods. In
scenarios 2 and 3 the adaptive Lasso yields the higher RCV, but the models are not as sparse as the
stepwise methods. Although the stepwise methods (stepCL, stepCL2, stepAdaCL) result in including
the least variables in the model, its discriminative ability in terms of AUC, as shown in Table 2, is
comparable with the other methods that tend to select a larger model with more variables.
Table 1. Simulation results for all four scenarios based on 1000 replications. The table summarizes the complexity of the models in
terms of correct non-zero estimates. The first column to the left shows the median value (1st and 3rd quantile) of the correct
variables included in the model. The second column is the median (1st and 3rd quantile) of the total variables each model selects.
The third column is the average RCV (standard deviation), the ratio of the correct variables over the total variables selected. The
stepCL, stepAdaCL and stepCL2 are the stepwise methods and CL, CL2 are the global optimization methods.
Scenario
Methods
(n = 100)
1 2 3 4 1 2 3 4 1 2 3 4
Number of true βj0 Median (1QN-3QN) Total Variables Median (1QN-3QN) RCV
1 Mean (sd)
stepCL 3 5 4 5 3 6 6 7 0.85 0.78 0.71 0.79
(2–3) (4–6) (4–4) (5–6) (2–4) (5–7) (5–6) (6–8) (0.18) (0.17) (0.15) (0.15)
stepCL2 3 6 5 6 3 7 6 9 0.80 0.77 0.82 0.75
(3–3) (5–7) (4–5) (5–7) (3–3) (6–8) (6–7) (8–10) (0.18) (0.16) (0.11) (0.15)
stepAdaCL 3 5 4 5 3 8 7 6 0.82 0.70 0.62 0.71
(2–3) (4–6) (4–5) (4–6) (3–3) (5–10) (6–8) (5–9) (0.18) (0.20) (0.14) (0.20)
CL (L0+L1) 3 6 7 7 4 8 9 9 0.72 0.77 0.82 0.75
(3–3) (5–7) (7–8) (6–8) (3–5) (7–10) (8–10) (8–11) (0.19) (0.13) (0.12) (0.13)
CL2 (L0+L2) 3 8 9 9 7 13 19 22 0.48 0.64 0.47 0.41
(3–3) (7–10) (7–10) (7–10) (5–9) (10–17) (15–26) (17–26) (0.19) (0.18) (0.18) (0.14)
Lasso (L1) 3 7 7 8 4 11 9 17 0.66 0.67 0.77 0.55
(3–3) (6–9) (6–8) (7–9) (3–9) (7–21) (7–14) (10–26) (0.33) (0.26) (0.24) (0.23)
Adaptive Lasso 3 12 8 9 3 15 8 15 0.79 0.81 0.88 0.65
(2–3) (9–13) (6–9) (8–11) (3–6) (11–17) (6–11) (11–20) (0.30) (0.14) (0.15) (0.17)
1RCV ¼ # correctly selected variables with true βj0# total variables selected
Table 2. Simulation results for all four scenarios based on 1000 simulated datasets. The table summarizes the performance of the
models for all scenarios. The Brier score and the area under the ROC curve are calculated on the testing set.
Scenario
Methods
1 2 3 4 1 2 3 4
Brier score Mean (sd) AUC (test) Mean (sd)
stepCL 0.09 0.12 0.08 0.12 0.95 0.92 0.96 0.91
(0.01) (0.02) (0.02) (0.02) (0.02) (0.03) (0.02) (0.03)
stepCL2 0.10 0.11 0.07 0.11 0.94 0.92 0.97 0.92
(0.02) (0.02) (0.02) (0.02) (0.02) (0.03) (0.01) (0.03)
stepAdaCL 0.10 0.13 0.08 0.14 0.95 0.91 0.96 0.89
(0.02) (0.03) (0.02) (0.03) (0.01) (0.03) (0.02) (0.03)
CL (L0+L1) 0.10 0.11 0.07 0.12 0.96 0.94 0.98 0.93
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) (0.02)
CL2 (L0+L2) 0.12 0.12 0.09 0.15 0.94 0.93 0.97 0.90
(0.01) (0.01) (0.02) (0.01) (0.01) (0.03) (0.02) (0.03)
Lasso (L1) 0.11 0.11 0.08 0.12 0.96 0.93 0.97 0.92
(0.02) (0.02) (0.02) (0.02) (0.01) (0.02) (0.01) (0.02)
Adaptive Lasso 0.11 0.09 0.07 0.11 0.95 0.95 0.98 0.93
(0.03) (0.02) (0.03) (0.02) (0.02) (0.02) (0.02) (0.02)
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The stepCL2 method also has remarkable performance both in terms of sparsity and predictive
discrimination. Considering the trade-off between model complexity and performance, the proposed
stepwise combined penalty approach achieves a good balance between parsimony, including less
variables and maintaining a high predictive accuracy that is comparable with state-of-the-art
methods. We should mention that in scenarios 2, 3, and 4 none of the methods select all of the k
informative variables, however, for the stepwise method the AUC of the ROC curve on the testing set
is greater than 90%, indicating a good discrimination accuracy by including the least variables in the
model. In all scenarios, we found that the stepCL2 method has comparable performance to stepCL
and is superior to adaptive Lasso and Lasso.
In Table 2, we present results regarding the predictive classification accuracy of the methods by
the AUC of the ROC curves. We report the Brier score (Brier, 1950) as a measure of the accuracy of
predictions, defined as
Brier ¼ 1
n
Xn
i¼1
p^i  yi
 2
It is given by the squared distance between the patients observed status yi and the predicted
probability bpi. The decision space for the Brier score is the interval [0,1] and generally the lowest
the Brier score, the better the classification rule. If the predicted probability is 0.5 for each individual,
the Brier score of 0.25 would indicate that the classification rule is a random one.
Empirical results from our simulations show that even for settings where n > d, the stepwise
method gives the sparsest solutions while maintaining classification performance measures as good
as Lasso and adaptive Lasso. The CL2 method tends to select big models, due to the L2 norm which
shrinks coefficients toward zero without variable selection. Thus when a is close to 1, the model will
behave similar to ridge regression and the resulting model will be complex in terms of the number of
predictors. On the other hand, when a is closer to 0, the CL2 and stepCL2 methods will borrow more
of the characteristics of the L 0 norm and will result in sparser models.
In our simulations, we also considered the case where there is no correlation among predictors
(results not shown in the table as we do not consider it a realistic scenario). We repeated scenario 2
with the only alteration of setting ρ ¼ 0. Results were in the same direction as in scenario 2 shown in
Table 1 and Table 2. That is, the stepwise methods perform better than all the other methods in
terms of model complexity resulting in the sparsest models with a high classification performance.
Furthermore, we examined the situation where there are no predictors in the data associated with
the outcome. In that case that the true model is the null model, none of the methods identified the
true model. Again, running through the second scenario with d = 150 predictors with none being
informative for the outcome, the stepCL method selected a median of five variables, whereas the
other methods selected between 14 (AdaLasso, CL) and 19 (CL2). We observed the same pattern in
the results for repeating the first scenario with d = 50 uninformative predictors, where none of the
methods selected the true model but the stepwise methods produced the sparsest solutions.
Application- real data analysis
To illustrate the applicability of the proposed method, we applied the stepwise method on a real
example involving protein measurements. The dataset contained n = 53 patients with baseline
measurements of d = 187 proteins. To maintain confidentiality, the names of the proteins are not
revealed. For the presentation of the results and keeping the study anonymized we renamed the
proteins to X1;X2; . . . ;X187. The objective is to extract potential candidate markers discriminating
responders from non-responders based on patients’ protein levels. We apply our proposed stepwise
combined penalty approach with the aim to select a small set of proteins that can sufficiently predict
response to the treatment. We compare our approach with the commonly used Lasso and adaptive
Lasso, but also with the global optimization penalized methods CL and CL2.
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The regularization parameters were not tuned by cross-validation, due to the relatively small
sample size (n = 53). The tuning was done using the bootstrap method in the following way; for a
grid of values of (a; λÞ, we trained the models on B = 100 bootstrapped datasets (drawing samples
with replacement from the original data) and evaluate their classification performance (in terms of
AUC) on the original data. For each combination of the tuning parameters (a; λÞ, the models were
trained on B bootstrapped sets and validated on the testing set (original data) and the average AUC
(over the B bootstrapped samples) was reported together with its standard deviation. The config-
uration of (a; λÞ that corresponds to the median of the AUC in interval A, as described above in
Section 3.2 ‘Tuning of parameters’, was chosen.
The results show that the stepwise methods yield the sparsest models by selecting eight variables
(stepCL) and nine (stepCL2) accordingly, whereas the other methods select between 22 (CL2) and 26
(Lasso). It is noticeable that the classification performance of the stepwise method is as good as the
other variable selection methods, even including the least predictors. In order to evaluate the
performance of the models and in the absence of an external validation dataset we use bootstrapping.
We applied all the methods on another B = 1000 bootstrapped datasets of the protein data, by
sampling with replacement, and the frequencies of the top 10 selected variables by all methods are
reported in Figure 3. This resulted in 16 unique proteins.
Figure 3. Heatmap of the frequencies (%) of the top 10 variables selected over B=1000 bootstrapped datasets of the protein data.
The first column (stepCL) is ordered by decreasing frequencies of the top 10 variables selected by all methods. In dark colour are
the higher frequencies (>30%) and the lighter colours depict the lower frequencies.
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This figure shows that the proteins that were frequently selected by the stepCL and stepCL2
methods are also frequently selected by the Lasso and adaptive Lasso. Note that the stepwise methods
have lower frequencies of the selected variables, because selection of larger models will automatically
increase the number of selection for individual variables.
Figure 4 shows boxplots of the total number of variables included in the model over the bootstrap
evaluations. The stepwise method yields consistent model selection by selecting a median of eight
variables for stepCL and stepCL2, whereas the Lasso and adaptive Lasso have a big variability on the
complexity of the model selected. The AUC of the ROC curves that is used as a measure of
classification performance of the methods on the bootstrapped datasets and their distribution is
shown in Figure 5. The stepwise methods tend to always select the most sparse models more
systematically, while maintaining a very good classification performance.
Conclusion
In this paper, we have proposed a stepwise forward approach for model selection in the framework
of penalized regression using a penalty that combines the L0 norm, which is based on the number of
coefficients, with L1 norm which is based on the size of coefficients or L2 norm which take into
Figure 4. Boxplots of the total variables selected by all methods over the B=1000 bootstrapped datasets of the protein data.
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account the grouping effect. The aim of the proposed method is to find a model that includes as few
and relevant variables as possible on one hand, while maintain good predictive performance on the
other hand. The combined penalization term CLαε βð Þ that was introduced by Liu and Wu (Liu &
Wu, 2007) was limited to moderate datasets due to limitations of the optimization algorithm.
Considering the heuristic stepwise forward approach, we can apply the penalization CLα βð Þ and
CL2α βð Þ to high-dimensional data by using the BFGS algorithm which is found to work well in
practice for non-convex and non-smooth functions (Lewis and Overton, 2009 ; Lewis and Overton,
2013; Curtis and Que, 2015 ). As a result, the practical implementation of the stepwise penalization
method is simpler and more efficient.
We find that the combined penalty does achieve the goal of sparser selection compared to the
Lasso and adaptive Lasso while at the same time retaining the same or very similar predictive
performance. While the stepwise method is only an approximation to the true optimal solutions it
appears to approximate the true optimal solution as well or on occasion even better than the global
optimization routine and reduces the computational time considerably. Tuning of the regularization
parameters (a; λÞ can, however, take a few minutes. Tuning is an important aspect of penalization
methods and will be further explored and improved in future work.
Simulation results and a real data application show that the proposed method yields sparser
models, while maintaining a good classification performance. This is an essential consideration for
classification and screening applications where the goal is to develop a test using as few features as
possible to enhance the interpretability and, potentially, the reproducibility of the results, as well as
to control the cost of the implementation of the test. Overall, we found that our method provides a
sparser model while maintaining similar prediction properties as compared to other methods. We
Figure 5. Boxplots of the AUC of the ROC curves by all methods over the B=1000 bootstrapped datasets of the protein data.
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hope that this paper could be a first step to learn more about the theoretical properties of this
method, which seems to be worth further investigation.
Furthermore, it would be of great interest to extend the forward stepwise method to the stepwise
bidirectional approach, considering at each step of the algorithm which variables can be included
and excluded (forward and backwards variable selection) in the model. As future work we also
consider to apply our method to regression problems for variable selection with a continuous
response as well as time-to-event data.
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A Bayesian model to estimate the cutoff
and the clinical utility of a biomarker assay
Eleni Vradi,1,2 Thomas Jaki,3 Richardus Vonk1
and Werner Brannath2
Abstract
To enable targeted therapies and enhance medical decision-making, biomarkers are increasingly used as screening and
diagnostic tests. When using quantitative biomarkers for classification purposes, this often implies that an appropriate
cutoff for the biomarker has to be determined and its clinical utility must be assessed. In the context of drug
development, it is of interest how the probability of response changes with increasing values of the biomarker.
Unlike sensitivity and specificity, predictive values are functions of the accuracy of the test, depend on the prevalence
of the disease and therefore are a useful tool in this setting. In this paper, we propose a Bayesian method to not only
estimate the cutoff value using the negative and positive predictive values, but also estimate the uncertainty around this
estimate. Using Bayesian inference allows us to incorporate prior information, and obtain posterior estimates and
credible intervals for the cut-off and associated predictive values. The performance of the Bayesian approach is
compared with alternative methods via simulation studies of bias, interval coverage and width and illustrations on
real data with binary and time-to-event outcomes are provided.
Keywords
Bayesian model, cutoff estimation, predictive values, step function, diagnostic tests, clinical utility, response rates
1 Introduction
The development of diagnostic tests using biomarkers is now an integral part of the drug discovery and
development process. Biomarkers are used in enrichment to assist in patient selection and in the design of
clinical trials.1 In the ﬁeld of oncology, for instance, biomarkers are used to develop tests aiming to identify
and treat those who are more likely to respond and demonstrate a higher therapeutic beneﬁt. The adaptation of
these biomarkers-based tests for classiﬁcation purposes requires the assessment of the test performance and,
perhaps even more importantly, their clinical utility.
The evaluation of the diagnostic performance of a set of biomarkers is usually performed using Receiver
Operating Characteristic (ROC) curves, which plot the true positive rate (sensitivity) versus the false positive
rate (1-speciﬁcity) over all possible decision thresholds of the test. This is helpful in choosing the most
discriminating marker or set of markers.2 After choosing an accurate marker from a set of markers, an
appropriate threshold, or cutoﬀ value, must be determined such that it correctly classiﬁes patients as required.
Several strategies exist for selecting a cutoﬀ value. These may be based on numerical results around the
sensitivity and speciﬁcity, but may also include criteria based on biological or physiological information. Thus,
optimal thresholds may vary depending on the underlying criteria.3 Most commonly, the optimal cutoﬀ is chosen
as the one that optimizes a utility function. For example, the cutoﬀ that maximizes the number of correctly
classiﬁed patients or the cutoﬀ that minimizes the misclassiﬁcation cost. Because a utility function also requires
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information about cost or beneﬁt, which is not always available, the optimal cutoﬀ value is found by using criteria
related to ROC curves. Conﬁdence intervals around the cutoﬀ value are obtained either using the delta method or,
most commonly, by employing bootstrapping, though the coverage probabilities can be far from the desired level.4
ROC-based methods, however, do not provide information on the diagnostic accuracy for a speciﬁc patient.
Particularly in situations where a diagnostic test is used for classiﬁcation purposes, clinicians are mainly concerned
with the predictive ability of the test, approaching the result of the test from the direction of the patients. The
assessment of correct classiﬁcations can be facilitated by the use of positive and negative predictive values (PPV
and NPV, respectively). These predictive values are functions of the accuracy of the test and the overall prevalence,
and can be used to assess the clinical utility of a diagnostic test for classiﬁcation purposes.
Lunceford5 discussed the estimation of the clinical utility of a biomarker assay in the context of predictive
enrichment studies. The aim of his research was to select a cutoﬀ on a potentially predictive biomarker that can be
used as an enrollment criterion for patient selection. By implementing a Bayesian approach in estimating clinical
utility measures, he facilitates cutoﬀ decision-making, but without considering the actual cutoﬀ estimation.
In this paper, we are interested in estimating the cutoﬀ and the clinical utility of a biomarker, but most
importantly the uncertainty around the estimates of the parameters of interest. We propose a ﬂexible Bayesian
approach that can utilize prior information to estimate the cutoﬀ of a biomarker and its credible interval. By
modelling the probability of response with a step function using predictive values, we obtain estimates for the
cutoﬀ as well as for the predictive values of the test. Bayesian analysis allows us to assign probability distributions
to our prior beliefs for the parameters of interest and combine these with the data likelihood to yield a posterior
probability distribution representing our updated belief.
In section 2, we present the Bayesian model for estimating the cutoﬀ of a (continuous or ordinal) biomarker for
a binary outcome. The diﬀerent prior speciﬁcations for the cutoﬀ that we consider allow for some robustness of the
method. The ﬁnite-sample performance of the proposed Bayesian approach is demonstrated through a series of
simulations and compared with alternative frequentist methods like Maximum Likelihood approach and the PSI
index in Section 3. We also present applications of our method in Section 4 on real data for a continuous
biomarker and binary, as well as time-to-event endpoints. Finally, we conclude with a brief discussion.
2 Methods
2.1 Bayesian model for estimating the cutoff and its credible interval
In this section, we present a Bayesian model for estimating the posterior distribution of a cut-oﬀ value for a
biomarker, as well as its predictive values. Let X ¼ X1, X2, . . . ,Xnð Þ 2 R denote the continuous biomarker
measurements for n individuals and assume that X is available to be measured on all patients. Let
Y ¼ ðY1, Y2, . . . ,YnÞ denote the binary response variable, where Yi 2 f0, 1g for all i ¼ 1, . . . , n is the response
indicator (e.g. Yi ¼ 0 denotes the non-responders and Yi ¼ 1 the responder subjects). We do not make
assumptions about the distribution of the biomarker X and by convention it will be assumed that high values
of the marker X are associated with increased probability of response to a treatment.
We assume that the probability of response p can be modeled by a step function (Figure 1), in terms of positive
predictive value (PPV) and negative predictive value (NPV) of the biomarker assay. The PPV is deﬁned as the
Figure 1. Plot of the observed biomarker X measurements for y¼ 1 and y¼ 0 (black stars). The blue dots depict the probability of
response, p, when fitting a logistic model and the dashed red line shows p when it is modeled by a step function, and p1¼ 0.17,
p2¼ 0.95 and cp¼ 5.19 are the posterior means as estimated by the Bayesian model.
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conditional probability of response given a positive test result, i.e. P y ¼ 1jT þð Þ. Conventionally, for potential cutoﬀ
cp 2 R, the test is positive, T þ, if the biomarker exceeds the cutoﬀ, X  cp, and is negative otherwise. Similar
statements apply for the NPV which is deﬁned as the conditional probability that an individual is a non-
responder given a negative test result, i.e. P Y ¼ 0jT ð Þ ¼ P Y ¼ 0jX  cpð Þ. The model is speciﬁed in the
following way
YjX  Bernoulli pð Þ
pðxÞ ¼ P Y ¼ 1jX ¼ xð Þ ¼
p1 ¼ P Y ¼ 1jX  cpð Þ, for x  cp
p2 ¼ P Y ¼ 1jX4 cpð Þ, for x4 cp
8><>: ð1Þ
The p1¼ 1NPV expresses the probability of response given X is below the cutoﬀ value cp and p2¼PPV
expresses the probability of response given that X is greater than cp.
Logistic regression can be used for decision-making, i.e. to classify a subject as responder or not, only in
conjunction to a probability threshold, i.e. p ¼ 0:5.6 However, the advantage of using the step function is that
the cutoﬀ is a parameter of the model and therefore a Bayesian approach can be applied. The strong assumption
we make that the probability of response can be modeled by a step function is probably not always reﬂecting the
reality. However, it may serve as an approximating model in cases where there are two populations that have a
pronounced diﬀerence in the response rate. It follows from literature on misspeciﬁed models7,8 that even if the
model is misspeciﬁed, the estimates of the assumed step function are consistent for the parameter values for which
the assumed model minimizes the distance from the true distribution in terms of Kullback–Leibler (KL)
divergence.9
2.1.1 Prior specification
In a Bayesian setup, the idea is to represent the uncertainty about the parameters by a prior distribution. Prior
information can take into account subjective beliefs about the values of the parameters of the model. This external
information can be historical information from experiments, experts opinion or literature ﬁndings. A Bayesian
approach can thus be useful as it allows ﬂexibility combining the available prior knowledge on test characteristics
with new data. Importantly, incorrect prior information can lead to unreliable posterior estimates, and therefore
great attention should be paid to the choice of the prior. On the other hand, if good prior information is
available then the gain is in the precision of the estimates.
Here, the parameters p1, p2 and the cutoﬀ are assumed to have probability distributions reﬂecting the
uncertainty in their parameters values. For the probabilities of response p1 and p2, we consider distributions
that the support set is the interval (0, 1). Furthermore, we require that p24 p1. The simplest case is to assign
uniform priors, i.e.
p1  Unif ð0, 1Þ and p2  Unif ð p1, 1Þ ð2Þ
Other options may include Truncated Normal or Beta distributions.
For the cutoﬀ cp, we can consider an informative prior, if prior information is relevant and an uninformative
prior, when there is no information available, usually expressed by a uniform distribution. Finally, a weighted sum
of informative and non-informative priors can be considered to acknowledge potential prior-data conﬂict. We
propose here a two-component mixture of priors, which allow for robustness. The ﬁrst component of the mixture
prior is the informative part which expresses the subjective belief we have and is derived from prior experiments,
animal data or literature. Then, the second component is the weakly (or non-) informative part that ensures
robustness against potential prior-data conﬂict. We characterize a prior distribution as weakly informative if
the information that provides is intentionally weaker than whatever actual prior knowledge is available.
As discussed by Schmidli et al.,10 since one of the mixture components is usually vague, mixture priors will often
be heavy tailed and therefore robust. Let g1 be the probability density function (pdf ) of the uninformative
component and g2 the pdf for the informative part. The mixture prior can be expressed as
cp ¼ w g1 þ 1 wð Þ g2 ð3Þ
Vradi et al. 3
with
w  Betað1, 1Þ
The weight parameter w will be updated at each iteration by the Bayesian model as described in section 3.
2.1.2 Prior specification for constrained PPV
In this section, we present the case where the objective is to estimate a cutoﬀ associated with a targeted clinical
utility value by controlling the PPV of the test. For example, we might be interested in the posterior distribution of
the cutoﬀ expected to yield a PPV between 70% and 100% or a 1-NPV to be between 0 and 20%. Whether a cutoﬀ
that yields a pre-speciﬁed predicted value exists would of course depend on the relationship between the biomarker
and the response. The idea is then to incorporate the restriction on the predictive values via the prior information
and require that only information on the pre-speciﬁed domain is acceptable. In that case, the constraints can be
controlled through priors, e.g.
p1  Unif ð0, p2Þ and p2  Unif ð0:7, 1Þ
It is worth noting that even if the parameter is constrained such that the actual desired range is not achievable,
e.g. p2 =2 (0.7, 1), the method will result in the cutoﬀ value that is as close as possible to achieve this constraint (i.e.
the mode of the posterior density is on the lower bound of the constrained interval).
2.1.3 Posterior distribution
The posterior distribution of interest is formulated as
f cp, p1, p2jx, yð Þ / L p1, p2, cpjx, yð Þ  f ð p1Þ  f ð p2Þ  f ðcpÞ ð4Þ
where L p1, p2, cpjx, yð Þ is the likelihood function of the data and f ðÞ denotes the density of the prior and f ðjx, yÞ
the posterior density of the distribution of the parameters.
2.1.4 Maximum likelihood estimation
The log likelihood of the model described in section 2.1 is given by
logL ¼ L p1, p2, cpjx, yð Þ ¼
Xn
i¼1
yi log pð Þ þ 1 yið Þ log 1 pð Þ
with p as stated in equation (1) and n denotes the total sample size. The log likelihood function becomes
logL ¼
Xn1
i¼1
yi log p1ð Þ þ 1 yið Þ log 1 p1ð Þ þ
Xn2
i¼1
yi log p2ð Þ þ 1 yið Þ log 1 p2ð Þ
where n1, n2 denote the sample size for the population that has X  cp and X4 cp, respectively. The maximum
likelihood estimates bcp, bp1 and bp2 are obtained by ﬁrst minimizing logL with respect to p1 and p2, for given cp
and then maximizing the resulting proﬁle likelihood with respect to cp. One can see that bp1 and bp2 are just the
average response rates in the subsamples {xi  bcpg and {xi4 bcpg where xi is the observed value of X (see Appendix
3 for a similar argument for the population parameters).
3 Simulation study
In this section, we examine the bias of the estimated cutoﬀ under diﬀerent distributional assumptions for the
biomarker X via simulations. We compared the proposed Bayesian method with two frequentist approaches; the
maximum likelihood estimator (MLE) and the predictive summary index (PSI).11 The PSI estimates the optimal
cutoﬀ by maximizing the diﬀerence in predictive values for all possible cutoﬀs c and is expressed as
PSI ¼ maxc PPV cð Þ þNPV cð Þ  1
 
. The PSI is derived in the target (patient) population as a measure of the
goodness of the predictability in a diagnostic test, and thus is a more comprehensive measure than the Youden
index12 in a clinical setting. For the latter approach, the conﬁdence intervals are calculated by the bootstrap
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method by resampling the data B ¼ 500 times, calculating the dPSIj per sample j ¼ 1, . . . ,B and then taking =2
and 1 =2 quantiles of the dPSIj to construct a ð1 Þ 100% CI. For the Bayesian approach, the credible
intervals are obtained by using the empirical =2 and 1 =2 quantiles of the posterior distribution (quantile
method). A level of  ¼ 0:05 was used for both methods.
We include in our results the MLE of the parameters p1, p2, cp together with the 95% conﬁdence intervals (CI)
as a comparison. In general, maximum likelihood methods do not perform well when parameter estimates are on
the boundary of the parameter space,13 leading to some non-convergence issues. On the other hand, Bayesian
inference via MCMC algorithms permits full posterior inference even in the absence of asymptotic normality14 and
have no issues with parameter estimates on the boundary. In our simulation, we did not anticipate any
optimization issues regarding the optimization with the ML method.
We simulated 10,000 datasets on which we applied all methods. We also report the coverage probability and the
width of the credible and conﬁdence intervals over the simulation runs. The analysis for the MLE and PSI
estimation was done in R version 3.3.3.15 The 10,000 datasets were generated in R (for the MLE and
PSI estimation) and then exported to SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) (for the Bayesian
estimation), such that the analysis was consistent for all the methods. For the PSI method the R-package
‘‘OptimalCutpoints’’16 was used and for the proﬁle MLE the R-library ‘‘bbmle’’.17
The posterior computation was done by using Markov Chain Monte Carlo (MCMC). In our analysis we used
the Metropolis-Hastings18,19 iterative sampling method to approximate the posterior distribution and get posterior
estimates for the parameters in equation (4). Posterior computation was conducted using PROC MCMC
procedure in SAS. The burn-in consisted of 10,000 iterations, and 50,000 subsequent iterations were used for
posterior summaries. Convergence of the MCMC chain was checked for randomly selected number of iterations,
using diagnostic plots and the Gelman–Rubin convergence statistic as well as visually via trace plots, sample
autocorrelations and kernel density plots. The SAS and R code can be found in Appendix 1.
3.1 Simulation setting
3.1.1 Generating data using a step function and a logistic function
The true model that was used to generate the binary outcome y has one biomarker X. We consider six diﬀerent
simulation scenarios, each with n ¼ 200, and n ¼ 50. Furthermore, we assumed that the biomarker X follows
diﬀerent distributions as shown in Table 1. Each component of the response vector y is viewed as a realization of a
Bernoulli random variable with probability of success p, i.e. yjX  Bermoullið pÞ. In scenarios 1–4 and 6, the
generating model has response probability p expressed as a step function, with pðXÞ ¼ p1, if X  cp
p2, if X4 cp

, whereas
in scenario 5 the generating model is a logistic model with probability of response p ¼ eX1þeX.
Table 1. Six simulation scenarios assuming different distributions for the marker X, the true cp, p1 and p2, as well as different
generating models, a step function and a logistic function.
Scenarios
Distribution
of X 1 
2
1 2 
2
2 True cp True p1 True p2
Generating
Model
1 Normal  ¼ 7, 2 ¼ 1 7.30 0.10 0.80 Step function
2 Mixture Normal
(unequal
variances)
6.5 0.09 8 0.25 7.30 0.20 0.90 Step function
3 lognormal  ¼ 0, 2 ¼ 1 2 0.30 0.85 Step function
4 Ordinal with
4 levels
X¼ 1, 2, 3, 4 3 0.10 0.75 Step function
5 Normal  ¼ 7, 2 ¼ 2,
0 ¼ 3, 1 ¼ 0:5
(6.80) (0.41) (0.76) Logistic function
6 Normal 5 1 9 1 cp1 ¼ 6
cp2 ¼ 10
p1 ¼ 0:20,
p2 ¼ 0:60,
p3 ¼ 0:80
Step function
Note: For the latter generating model, the true parameters that are in parenthesis are the population parameters as calculated by minimizing the
Kullback–Leibler divergence.
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The primary purpose of including scenario 5 is to investigate the behavior of the Bayesian method (together
with the MLE and the PSI method), when the ﬁtted model is divergent from the true underlying model. For this
scenario, the true cp, p1 and p2 are not deﬁned by the data generating mechanism. In fact, it is known (see e.g.
7,8)
that the estimated parameters from the Bayesian and MLE method are consistent for the ones that minimize the
Kullback–Leibler divergence between the ﬁtted (step) model and the true (logistic) model. We give details on the
limiting population parameter in Appendix 1.
In scenario 4, we explore the case that the biomarker X is ordinal. The data were generated in the following way;
assuming X  Normal  ¼ 7, 2 ¼ 1  as in scenario 1, we calculate the quartiles of X that form the four levels of
the ordinal variable (the lowest quartile corresponds to category X ¼ 1 and the fourth quartile to X ¼ 4). Each
component of the response Y is a realization from a Bernoulli random variable with pðXÞ ¼ p1, if X ¼ 1, 2
p2, if X  3

Moreover, we are interested to address the case that the true generating model has two cutoﬀs and the ﬁtted
model assumes only one cutoﬀ (scenario 6 in Table 1). To simulate data for this scenario, scenario 6, we assumed
that pðXÞ ¼
p1, if X  cp1
p2, if cp15X  cp2
p3, if X4 cp2
8<: . If the data indicate the existence of two cut-oﬀ values, this might
indicate the existence of two subgroups with diﬀerent response probabilities. For the scenarios 2 and 6, we
assumed that the biomarker X follows a mixture of two normal distributions expressed as
X  Normal  ¼ 1, 2 ¼ 21
 þNormal  ¼ 2, 2 ¼ 22 .
3.2 Simulation results
This section describes the simulation results regarding the ﬁnite sample properties of the estimators from the
Bayesian method, the PSI index and the ML. In our results, we chose to report the Bayesian posterior mean, as
we consider it an adequate measure to summarize the posterior density and we found that the cutoﬀs were generally
similar whatever estimate kept from the posterior distribution among the mode, median or mean. In Tables 2 and 3,
we report the Bias of estimators for cp (Table 2), p1, p2 (Table 3) for scenarios 1–4 based on 10,000 simulation runs.
Coverage probability and interval width of the conﬁdence and credible intervals are shown in Tables 4 and 5.
For the Bayesian method, we also report results for four diﬀerent prior speciﬁcations. The ﬁrst, the naı¨ve case,
corresponds to a uniform prior (UP) in the interval of the range of the biomarker measurements. Note here that
with a uniform prior, it is well known20 that the Bayesian posterior mode corresponds to the ML estimator. Other
priors we considered are a perfect informative prior (denoted as IPP), an imperfect informative prior (denoted as
IPN) and two mixture priors (MixP and MixN) each with two components; a weighted sum of a uniform and
informative prior (UPþ IPP) and a uniform and imperfect informative prior (UPþ IPN), respectively. More
speciﬁcally, for the IPP prior, we assume a distribution for which the true cutoﬀ lies in an interval of high
probability, whereas for the IPN prior the true cutoﬀ lies in one of the tails of the distribution. An illustration
of the IPP and IPN priors used for scenario 1 can be found in Figure 2. Obviously, when the prior does not include
Table 2. Mean bias of the estimate of the cutoff bcp over 10,000 simulation runs for the Bayesian method, the MLE and PSI approach
for scenarios 1–4 for n¼ 50 and n¼ 200.
cp Bias
Methods Bayesian PSI MLE
Prior UP IPN IPP MixN MixP
Scenario 1 n¼ 200 3 104 1 103 1 104 2 104 8 104 0.288 4 103
n¼ 50 4 102 5 102 2 102 1 103 6 103 0.393 9 102
Scenario 2 n¼ 200 7 103 1 102 2 102 1 102 9 103 1 102 2 102
n¼ 50 1 102 1 101 8 102 3 102 3 102 6 104 0.173
Scenario 3 n¼ 200 1 102 4 102 5 104 4 102 2 103 3.447 3 103
n¼ 50 2 101 4 101 4 104 2 102 9 102 1.449 0.365
Scenario 4 n¼ 200 2 102 2 102 4 104 5 103 4 104 2 104 2 103
n¼ 50 8 103 4 102 7 103 2 102 7 103 3 102 0.996
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the true value of the cutoﬀ, then the posterior estimates are expected to be biased for ﬁnite sample sizes. The priors
for p1, p2 were taken as uniform distributions as given by equation (2).
Regarding the estimation of the cutoﬀ cp, in scenarios 1–4, results in Table 2 show that estimators using all
three methods behave similarly in terms of bias, resulting in nearly unbiased estimators. The Bayesian method
gives a much better coverage than the MLE and PSI methods for the scenarios where the marker is continuous
(Table 4). For the PSI method in scenarios 1 and 3, the bias of the estimate of cp is far too high in absolute terms
(see Table 2). Additionally, the coverage of the bootstrapped conﬁdence interval is far from the nominal level and
the interval width is much wider compared to the other methods. The Bayesian method performs either the same
or better compared to MLE and PSI in terms of bias and coverage both in case of the continuous and the ordinal
biomarker.
For all priors that we considered, the resulting estimators are on average unbiased for both n ¼ 200 and n ¼ 50.
As expected, with the robust mixture prior and the informative prior, estimates have the smallest bias on average.
The IPP prior gives a smaller interval width with the mixture prior second. Moreover, with the IPP prior we get
more precise estimates while obtaining the same or better coverage compared to the other prior speciﬁcations.
Table 3. Mean bias of the estimates of predictive values bp1 and bp2 over 10,000 simulation runs for the Bayesian method, the MLE and
PSI approach for scenarios 1 4 and for n¼ 200.
p1, p2 Bias
Methods Bayesian PSI MLE
Prior UP IPN IPP MixN MixP
Scenario 1
p1 7 103 7 103 7 103 7 103 7 103 3 102 1 104
p2 8 103 8 103 8 103 8 103 8 103 4 102 4 104
Scenario 2
p1 7 103 7 103 6 103 7 103 7 103 3 103 1 103
p2 9 103 1 102 1 102 1 102 9 103 8 104 2 104
Scenario 3
p1 5 103 2 103 4 103 4 103 4 103 5 102 1 103
p2 1 102 2 102 2 102 2 102 1 102 9 103 3 102
Scenario 4
p1 1 102 1 102 9 103 1 102 9 103 2 104 9 102
p2 8 103 5 103 5 103 5 103 5 103 4 103 5 102
Note: For the Bayesian method, we display the results for all different prior specifications.
Table 4. Mean coverage and width of the credible/confidence intervals of bcp over 10,000 simulation runs for scenarios 1–4 for n¼ 50
and n¼ 200.
cp Coverage Interval width
Methods Bayesian PSI MLE Bayesian PSI MLE
Prior UP IPN IPP MixN MixP UP IPN IPP MixN MixP
Scenario 1 n¼ 200 0.968 0.969 0.969 0.950 0.969 0.677 0.919 0.088 0.088 0.088 0.088 0.088 1.547 0.085
n¼ 50 0.972 0.971 0.979 0.971 0.970 0.588 0.722 0.892 0.628 0.353 0.656 0.553 1.522 0.174
Scenario 2 n¼ 200 0.962 0.962 0.962 0.964 0.967 0.858 0.797 0.183 0.184 0.179 0.185 0.178 0.649 0.136
n¼ 50 0.979 0.964 0.969 0.976 0.977 0.901 0.467 0.832 0.787 0.514 0.684 0.619 1.534 0.216
Scenario 3 n¼ 200 0.959 0.955 0.997 0.939 0.995 0.782 0.486 0.431 0.382 0.138 0.407 0.205 8.669 0.131
n¼ 50 0.980 0.889 100 0.979 0.985 0.905 0.188 2.448 1.321 0.178 1.803 1.464 5.410 0.642
Scenario 4 n¼ 200 0.984 0.976 0.999 0.995 0.999 100 0.993 4 104 0 0 0.005 0 0.083 0.042
n¼ 50 0.967 0.948 0.989 0.992 0.998 0.999 0.002 0.035 0.018 0.030 0.184 0.105 0.967 0.039
Note: The credible intervals for all the different priors are computed by the quantile method. Bootstrapping was used to calculate the confidence
interval for the PSI method and the profile CI are presented for the MLE method.
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To see how the prior aﬀects the estimation, we calculate the absolute diﬀerence between the estimated and true
value of the cutoﬀ over the simulation runs and we present the results for the Bayesian method for scenario 1 for
all diﬀerent prior speciﬁcations as shown in Figure 8 in Appendix 1. In Figure 8, we see that the absolute diﬀerence
between the estimate and the true value of cp was on average below 10%. As for the predictive values, we discuss
our ﬁndings for n ¼ 200 and show the results for the estimate of the cutoﬀ. Detailed ﬁgures for the predictive
values for n ¼ 50 can be found in Tables 6 and 7 in Appendix 1.
As shown in Tables 3 and 5, all methods performed well with good coverage and very small bias for both p1 and
p2. The bias of the estimates for the predictive values p1 and p2 was always below 1% for all scenarios. Coverage
probabilities for the credible intervals reach the nominal value for the Bayesian and the ML method but is not
always the case for the estimation of p2 when using the PSI index as seen, for example, in scenario 1 and scenario 3,
where the coverage probability for the PSI method is far from the nominal (Table 5). The length of the credible
interval (for the Bayesian method) was similar to the conﬁdence interval for the MLE and always narrower
compared to PSI.
For scenario 5 where the true model is generated assuming a logistic response curve, we estimated the cutoﬀ and
the corresponding probabilities of response by applying the Bayesian method as well as the MLE and the PSI
approaches. In that case, the true cutoﬀ is not directly deﬁned by the data-generating mechanism. However, the
population parameters are deﬁned by minimizing the KL divergence between the true (logistic) and the assumed
Table 5. Average coverage and width of the credible/confidence interval for the estimate of the predictive values p1 and p2 over
10,000 simulation runs for scenarios 1–4 and for n¼ 200.
p1, p2 Coverage Interval width
Methods Bayesian PSI MLE Bayesian PSI MLE
Prior UP IPN IPP MixN MixP UP IPN IPP MixN MixP
Scenario 1
p1 0.949 0.949 0.951 0.942 0.949 0.972 0.932 0.107 0.107 0.107 0.106 0.106 0.247 0.106
p2 0.949 0.946 0.949 0.939 0.943 0.879 0.946 0.177 0.178 0.178 0.175 0.178 0.233 0.182
Scenario 2
p1 0.946 0.946 0.948 0.945 0.944 0.959 0.938 0.151 0.150 0.150 0.151 0.150 0.192 0.151
p2 0.949 0.948 0.949 0.949 0.948 0.959 0.979 0.123 0.124 0.124 0.123 0.123 0.178 0.134
Scenario 3
p1 0.949 0.951 0.949 0.949 0.949 0.985 0.936 0.147 0.146 0.144 0.146 0.144 0.283 0.145
p2 0.955 0.941 0.954 0.953 0.956 0.558 0.980 0.206 0.211 0.197 0.206 0.199 0.244 0.204
Scenario 4
p1 0.949 0.927 0.948 0.946 0.948 0.938 0.994 0.120 0.118 0.117 0.118 0.118 0.122 0.345
p2 0.937 0.950 0.951 0.949 0.951 0.955 0.991 0.165 0.167 0.165 0.166 0.165 0.172 0.191
Note: The credible intervals for all the different priors are computed by the quantile method. Bootstrapping was used to calculate the confidence
interval for the PSI method and the CI are presented for the MLE method.
Figure 2. Density plots for the priors IPP and IPN. For the IPP prior, the true cutoff cp lies in a high probability region, while for the
IPN prior, the true cutoff value lies on the tail of the distribution.
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(step) model as discussed in section 2.1 and more detailed in Appendix 1. The results of the distribution of the
estimates of the parameters for scenario 5 for the three methods are shown in boxplots in Figure 3.
In this scenario, the Bayesian estimates are more consistent and have a smaller variability compared to the
MLE and the PSI method. As can be seen from the boxplots, the ML and the PSI methods result in heavy tailed
distributions for all the parameters and especially for the estimate of the cutoﬀ. The estimates concerning the
cutoﬀ and the predicted values obtained with the PSI method, diﬀer signiﬁcantly as compared to the other two
methods. This is partially due to the fact that the PSI optimizes a diﬀerent utility function than the Bayesian and
the ML approach. While the Bayesian and the ML methods use the likelihood as an objective function, the PSI
method seeks to maximize the diﬀerence between PPV and 1-NPV.
For scenario 6, the generating model assumes that there exist two cutoﬀ values and three response probabilities
p1, p2, p3 respectively. The Bayesian model we ﬁt to estimate the cutoﬀ and the corresponding predictive values,
assumes that there is only one cutoﬀ value. For simplicity, we used an UP prior for the Bayesian method. The
results of the ﬁtted model are shown in Figure 4. Focusing on the estimate of cp, we analyzed the results in more
Figure 3. Bayesian posterior mean (left boxplots), MLE (middle boxplots) and PSI (right boxplots) estimators for the parameters cp
(left panel), p1 (middle panel), p2 (right panel), over 10,000 simulation runs for scenario 5. The black horizontal dashed lines are the
population parameters as calculated by minimizing the Kullback–Liebler divergence.
Figure 4. Boxplots of the Bayesian posterior mean (left boxplots), MLE (middle boxplots) and PSI (right boxplots) estimators for cp
(left panel), p1 (middle panel), p2 (right panel), over 10,000 simulation runs for Scenario 6. The black horizontal dashed lines
correspond to the true values of cp1, cp2, p1, p2, p3.
Vradi et al. 9
detail. We checked whether the obtained posterior distribution was bimodal, and if so, we reported the two modes.
To check for bimodality, i.e. if the posterior density function has two peaks, we used the Hartigan’s dip test for
unimodality.21 A p-value less than 0.05 is taken to indicate non-unimodality (it means at least bimodality).
Figure 5 shows the distribution of the estimated cutoﬀs when posterior density is judged to be unimodal (5733
out of 10,000 simulations) and when it is found to be a bimodal posterior distribution (4267 out of 10,000
simulations). Looking across all simulations, we see that the cutoﬀ is somewhere between the two true cutoﬀs.
When only a single mode is identiﬁed, there is a clear tendency to be close to the second true cutoﬀ cp2 ¼ 10. When
two modes are found, the underlying two true cutoﬀs are estimated reasonably well despite the model
misspeciﬁcation.
4 Application
4.1 The prostate cancer data
We consider the prostate speciﬁc antigen (PSA) study of 12,000 men aged 50–65, which was a randomized study
with a beta-carotene group as the treatment group vs. a placebo group. A substudy reported by Etzioni et al.22
analyzed serum levels of total PSA (on the log scale) for 683 subjects. The dataset is described in literature2,23
where you can ﬁnd additional details about the study, which was analyzed from a non-Bayesian perspective. The
primary scientiﬁc question under investigation was whether PSA could be used to diagnose prostate cancer, and
was found that the total PSA is a signiﬁcant predictor of the occurrence of cancer with fairly good accuracy. Albeit
the good diagnostic ability of the marker PSA, we are interested in estimating a cutoﬀ that takes into account the
clinical beneﬁt of this marker.
In this paper, we considered response to a treatment as the outcome of interest but the method can be used also
when we refer to diagnostic tests, where the outcome is presence of disease or not. We analyzed the data described
above by applying our Bayesian method to estimate the cutoﬀ related with disease rates. Probabilistic statements
are derived for the optimal cutoﬀ as well as the predictive values of the marker (logPSA). We assume a uniform
Figure 5. Distribution of the modes of the posterior distribution for the estimated cp, over 10,000 simulation runs for Scenario 6
estimated by the Bayesian model. If the posterior density is unimodal, then the only mode of the distribution is plotted (noSim¼ 5733)
(left boxplot). In case the posterior distribution is bimodal (noSim¼ 4267), then the two modes are plotted (middle boxplots). In the
right boxplot, the black lines correspond to the true values of cp1¼ 6, cp2¼ 10.
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prior for the cutoﬀ in the interval (10,10) and priors for the predictive values deﬁned as in equation (2). We also
report the ML estimator and the PSI index.
Figure 6 shows the posterior distributions for the cutoﬀ (left panel) and the predictive values p1 and p2
(middle and right panels respectively). The MLE of the cutoﬀ was found equal to 1.29 with 95% CI
(1.271.31), while the posterior mean of the cutoﬀ was 1.30 with 95% credible interval (1.271.38). The PSI
index, which we remind that maximizes a diﬀerent objective function, estimates the optimal cutoﬀ to be 3.63 with
95% bootstrapped CI (2.003.77). At that cut-oﬀ, the PPV and 1-NPV was equal to 1 and 0.32, respectively. The
Bayesian posterior mean for p1 and p2 was found equal to 0.18 with 95% credible interval (0.150.21) and 0.75
with 95% credible interval (0.700.79) respectively. The MLE for p1 was 0.18 with 95% conﬁdence interval (0.15–
0.21) and for p2 was 0.75 with 95% conﬁdence interval (0.68–0.81).
4.2 Application on survival data: Weibull model for melanoma data
To illustrate that the proposed approach is useful for more complex settings, we consider identifying the
appropriate cutoﬀ for a time to event endpoint. For the following applications on time to event data,
we assume the following: let Ti denote the event time for subject i. Due to censoring, instead of observing Ti,
we observe the bivariate vector (minðTi, CiÞ, i) where i ¼ IðTi  CiÞ with I the indicator function and Ci the
censoring time.
The data used are the melanoma dataset available from the R package timereg.24 The data consist of
measurements made on patients with malignant melanoma and patients with a thick tumor are thought to have
an increased chance of death from melanoma, thus the objective is to estimate a cutoﬀ value on (the log scale of)
the tumor size such that the patients below and above the cutoﬀ have a pronounced diﬀerence in their hazard rates.
We run the analysis using the R package MHadaptive25 and we used uniform priors for all the parameters. The
R-code is available upon request from the author.
To set up the model in the survival setting, the thickness of the tumor on the log scale is denoted by X, T denotes
time to death and is assumed to have a Weibull distribution with shape parameter r and scale parameter .
The assumption is that, based on the thickness of the tumor, we can estimate a cutoﬀ cp such that the two groups
deﬁned by cp have diﬀerent hazard functions. Therefore, the shape and scale parameter for the patients whose
thickness of their tumor is below cp is r1 and 1, respectively, and accordingly, r2 and 2 for those patients
with X4 cp.
TjX  Weibull r, ð Þ with r ¼ r1, if X  cp
r2, if X4 cp

and  ¼ 1, if X  cp
2, if X4 cp

Figure 6. Plot of the posterior distribution for the parameter cp (left panel), p1 (middle panel), p2 (right panel) estimated by the
Bayesian model. The red vertical lines denote the median of the distribution.
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Figure 7(a) shows the posterior densities for the cutoﬀ, the shape and scale parameters. We took the medians of
the posterior densities as point estimates for each parameter. In Figure 7(b) we plot the survival curves, estimated
with the Kaplan–Meier estimate, for the patients below and above the posterior cutoﬀ estimate, which was taken
as the posterior mean equal to bcp ¼ 5:38 with 95% credible interval (5.07–5.86). In the same ﬁgure, we plot the
survival curves for the Weibull model with dashed lines. As seen from the plot, the survival probability decreases
with higher tumor thickness value. To test whether the survival curves for the patients below and above the
estimated cutoﬀ value diﬀer signiﬁcantly, we applied the log-rank test which showed that there is a signiﬁcant
diﬀerence in survival (p<<0.05). Figure 7(c) shows the hazard function for the two groups by plugging in the
estimated shape and scale parameters, i.e. the hazard function for the Weibull model becomes
hðtÞ ¼
r1
1
ð t1Þ
r11, if X  cp
r2
2
ð t2Þ
r21, if X4 cp
(
, with r1, 1, r2, 2 taken as the means of the posterior densities.
5 Discussion
To enable targeted therapies and enhance medical decision-making, biomarkers are increasingly used in diagnostic
tests. When using quantitative biomarkers for classiﬁcation purposes, deﬁning a reliable cutoﬀ value for the
biomarker is a critical step in the drug development process, as the patient selection process in the subsequent
development steps may depend on this value. Although classiﬁcation probabilities, sensitivity and speciﬁcity, are
considered more relevant to quantify the inherent accuracy of the test, predictive values quantify the clinical
utility of the test.
Figure 7. (a) Histograms of the posterior distributions for the cutoff (left panel), the shape parameters r1 and r2 (middle panels) and
scale parameters 1 and 2 (right panels) for the Weibull model fitted to the melanoma data. The red vertical lines correspond to the
posterior median of the distribution. (b) Survival curves for the patients above and below the estimated cutoff cp¼ 5.38, taken as the
posterior median of the posterior density. The solid lines are the Kaplan–Meier curves and the dashed lines the Weibull survival
curves. (c) Plot of the hazard function for the groups below and above the cutoff estimated by the Weibull model by plugging in the
posterior means of the parameters r1, 1, r2, 2.
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We have proposed a Bayesian method to estimate the cutoﬀ value of a biomarker assay using the predictive
values, and also determine the uncertainty around these estimates. We used a step function, which serves as an
approximate model facilitating classiﬁcation into two groups that have a pronounced diﬀerence in their response
rates. The advantage of using the step function is that the cutoﬀ and predictive values are parameters of the model.
Even in the case that the assumption of a step function is strong and the model is misspeciﬁed, the estimates of the
assumed step function are consistent for the parameter values for which the assumed model minimizes the distance
from the true distribution in terms of Kullback–Leibler divergence.7,8 A more careful investigation of this
approach is worth further exploration.
Alternative approaches in classiﬁcation problems using logistic regression are frequently employed in practice,
for example using a probability threshold of p ¼ 0:5 to classify patients, or choose p such that the Brier score,26 a
measure of accuracy of predictions, is minimized. However, these methods do not directly address the goal of
population separation with regard to positive and negative predictive values. Moreover, they do not directly
provide credible or conﬁdence intervals for the parameters of interest which was one of the major goals of
the proposed method. Nevertheless, we have compared the Bayesian approach with these methods and found
that the estimated parameters of cp are more biased compared to the Bayesian estimates. Detailed ﬁgures can be
found in Appendix 1.
The proposed Bayesian approach allows for the estimation of the distribution of the cutoﬀ for continuous and
ordinal biomarkers and permits probabilistic statements about the cutoﬀ values and, say, the response rates in the
two groups. Together with the potential incorporation of prior information, this is deemed useful especially in
the earlier phases of drug development. Results suggest that the proposed Bayesian method is very tractable in
estimating the parameters of interest, resulting in point estimators (e.g. posterior mean) that are practically
unbiased in all scenarios, for all prior constellations and sample size assumptions.
In this article, we presented four diﬀerent prior speciﬁcations, including uninformative, informative, and
mixture priors. In all cases, estimation gave satisfying results. Especially when more accurate prior information
is available, the estimated parameters are nearly unbiased with high precision and good coverage. We suggest a
mixture prior that works well in practice, as it is robust towards potential prior-data conﬂict. For a dataset of
n ¼ 200 observations, the Bayesian approach takes 6.3 s to run on a windows machine with processor Intel
Xeon CPU E7-8867 v3 @ 2.5GHz, compared to frequentist approaches (MLE 0.15 s and for PSI 3.7 s together
with the bootstrapped CI). Although the computational time for the proposed approach is increased, as is the case
for Bayesian methods, is not prohibitive.
The approach described in this article can be used as a basis for further investigation. The suggested method
was applied to a single biological marker, but it can be generalized to multiple markers. One way to deal with
multiple markers is to estimate a composite score for each patient using a combination of markers (under some
working model, for example, under the logistic model), and then consider this score as the new marker.
Furthermore, it would be of great interest to consider the generalization of the method to estimate multiple
cutoﬀs that can be used potentially for subgroup identiﬁcation. In that case, model selection can be used to
decide how many cutoﬀs (indicating the number of subgroups) the model can have according to the data.
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Appendix 1. Bias, sample size and prior specification
We explored in a simulation study the performance of the Bayesian method in terms of the (absolute) diﬀerence
of the estimated cp from the true value of the cutoﬀ for diﬀerent sample sizes (n¼ 50, 75, 100, 150, 200, 500).
As expected, when the sample size increases, the bias is shrinking towards zero as we can see in Figure 8.
In Tables 6 and 7, we present simulation results concerning the predictive values for a sample size of n ¼ 50.
These results are complementary for the simulations described in section 3.2. We report the Bias, Coverage and
interval width for scenarios 1–4 and for all methods. For the Bayesian method, even with a small sample size, the
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bias of the parameters (on absolute scale) is always less than 4% on average. For the PSI and ML method, the bias
of the estimates is small, whereas the coverage does not always reach the nominal level and the interval widths are
always slightly bigger than the Bayesian method.
In Figure 9, we see the distribution of the absolute diﬀerence of the estimated cp from the true value of the
cutoﬀ over the 10,000 simulation runs, for the Bayesian method when we consider diﬀerent priors. The results
are presented for data generated as in Scenario 1 with a sample size of n¼ 50. Even with a small sample size, the
bias is always smaller than 10% on average. When the prior is informative precise then we achieve the smallest
bias, whereas when we consider a robust mixture of precise and uniform prior the bias is slightly higher but
still very small.
Table 7. Average coverage and width of the credible/confidence interval for the estimates of the predictive values p1 and p2 over
10,000 simulation runs for scenarios 1–4 for n¼ 50.
p1, p2 Coverage Interval width
Methods Bayesian
PSI MLE
Bayesian
PSI MLEPrior UP IPN IPP MixN MixP UP IPN IPP MixN MixP
Scenario 1
p1 0.956 0.969 0.957 0.961 0.955 0. 986 0.914 0.235 0.230 0.223 0.232 0.231 0. 287 0.217
p2 0.975 0.949 0.951 0.969 0.969 0.772 0.976 0.365 0.369 0.352 0.364 0.359 0.292 0.372
Scenario 2
p1 0.952 0.968 0.951 0.952 0.949 0.943 0.882 0.308 0.309 0.298 0.306 0.303 0.333 0.292
p2 0.971 0.947 0.951 0.966 0.964 0.957 0.969 0.258 0.269 0.256 0.258 0.256 0.300 0.290
Scenario 3
p1 0.960 0.971 0.946 0.962 0.951 0.969 0.897 0.309 0.314 0.282 0.302 0.294 0.395 0.291
p2 0.982 0.885 0.965 0.968 0.981 0.814 0.902 0.416 0.427 0.368 0.411 0.390 0.356 0.443
Scenario 4
p1 0.956 0.927 0.956 0.954 0.960 0.954 0.991 0.243 0.243 0.242 0.248 0.244 0.279 0.443
p2 0.950 0.949 0.951 0.951 0.955 0.949 0.987 0.315 0.317 0.314 0.320 0.317 0.407 0.487
Note: The credible intervals are computed by the quantile method. Bootstrapping was used to calculate the confidence interval for the PSI method and
the profile CI are presented for the MLE method.
Table 6. Mean bias of the estimate of the predictive values p1 and p2 over 10,000 simulation runs for the Bayesian method, the MLE
and PSI approach and scenarios 1–4 and for n¼ 50.
p1, p2 Bias
Methods Bayesian
PSI MLEPrior UP IPN IPP MixN MixP
Scenario 1
p1 3 102 3 102 3 102 3 102 7 103 4 102 4 102
p2 3 102 4 102 3 102 3 102 8 103 9 102 8 102
Scenario 2
p1 3 102 2 102 2 102 3 102 2 102 3 102 6 102
p2 4 102 4 102 3 102 3 102 3 102 4 103 5 102
Scenario 3
p1 2 102 2 103 2 102 1 102 2 102 7 103 6 102
p2 5 102 1 101 5 102 6 102 5 102 8 102 1 101
Scenario 4
p1 4 102 4 102 4 102 4 102 4 102 3 103 1 101
p2 2 102 2 102 2 102 2 102 2 102 6 103 5 102
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Figure 8. Boxplots of the absolute difference between the estimate and the true value of the cutoff cp over 10,000 simulation runs
for Scenario 1 for varying samples sizes (n¼ 50, 75, 100, 150, 200, 500). Results shown for the Bayesian method with a uniform prior.
The posterior mean was used as an estimate for the cutoff.
Figure 9. Boxplots for the absolute difference between the estimate bcp and the true value of cp estimated with the Bayesian model
over 10,000 simulation runs for Scenario 1. In this simulation, we used n¼ 50 samples for the case of (from left to right) an Informative
Prior Non-precise (IPN), an Informative Prior Precise (IPP), a Mixture Prior Non-precise (UPþ IPN), a Mixture Prior Precise
(UPþ IPP) and a Uniform Prior (UP).
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2 Comparison with other methods
We considered the simulated data from scenario 2 (generating model step function) and scenario 5 (generating
model logistic function) as examples to show the results regarding the ﬁt of the logistic with the choice of p ¼ 0:5
and the method that estimates p as the value minimizes the Brier score. Results are shown in Figure 10, where we
see that the estimated parameters by the logistic model with the choice of p ¼ 0:5 are more biased compared with
the Bayesian approach. For scenario 5, the posterior means by the proposed approach are similar to the method
that estimates p as the value that minimizes the Brier score but the latter approach results in much higher
variability. However, results diﬀer from the method that used the probability cutoﬀ of p ¼ 0:5, where we see
that it underestimate the true parameters.
3 Conditional Kullback–Leibler divergence between the theoretical and fitted model
3.1 Estimation of the predictive values
Let us assume that the data generating function of the true model is a logistic function, i.e. YjX  Bernoullið pÞ,
with link function logit pð Þ ¼ X, pðxÞ ¼ eX
1þ eX and joint probability distribution function g x, yð Þ. The conditional
distribution of YjX is G and g yjxð Þ the conditional density. Let us now consider that the ﬁtted model assumes a
step function for the probability of response with YjX  BernoulliðqÞ, qðxÞ ¼
q1, if x  cp
q2, if x4 cp
8<: and corresponding
conditional probability distribution F. The joint probability distribution function is f ðx, yÞ and f yjxð Þ the
conditional density. We would like to show that the estimates of the parameters in the step model are the ones
that minimize the Kullbaclk–Leibler (KL) divergence between the two probability distributions F and G. That is,
the expectation of the log diﬀerence between the conditional probability of data in the original distribution with
the approximate distribution.
Figure 10. Boxplots of the estimated parameters cp, p1, p2 (left, middle and right plots, respectively) by the Bayesian method, the
Logistic regression with a cutoff at p ¼ 0:5 and by minimizing the Brier score. Results shown for 10,000 simulation runs for scenario 2
where the generating model is a step function (upper panel) and scenario 5 where the generating model is logistic (lower panel). The
black horizontal lines correspond to the true values of the parameters.
Vradi et al. 17
The conditional Kullbaclk–Leibler divergence between the two probability distributions F and G is deﬁned as
DKLðGjjF Þ ¼
Z
X2A
gðxÞ
Z
Y2B
gð yjxÞlog g yjxð Þ
f yjxð Þ dy dx
where gðxÞ is the pdf of X, where X 2 A and Y 2 B.
We ﬁrst calculate the inner integral
R
Y2B gð yjxÞlog g yjxð Þf yjxð Þ dy ¼
EG y log
p xð Þ
q xð Þ þ 1 yð Þ log
1 p xð Þ
1 q xð Þ
 
¼¼
EG y log
p xð Þ
q1
þ 1 yð Þ log 1p xð Þ1q1
h i
, for X  cp
EG y log
p xð Þ
q2
þ 1 yð Þ log 1p xð Þ1q2
h i
, for X4 cp
8><>:
¼
p xð Þlog p xð Þq1 þ 1 p xð Þð Þ log
1p xð Þ
1q1 , for X  cp Ið Þ
p xð Þ log p xð Þq2 þ 1 p xð Þð Þ log
1p xð Þ
1q2 , for cp5X IIð Þ
8<:
We need to minimize DKLð gð yjxÞjjf ð yjxÞÞ over X, assuming that X has pdf gðxÞ and X 2 0, cp½  [ðcp,1. For a
given cp, we estimate q1 and q2 by minimizing
D
ðIÞ
KLð gð yjxÞjjf ð yjxÞÞ ¼
Z cp
0
g xð Þ p xð Þlog p xð Þ
q1
þ 1 p xð Þð Þ log 1 p xð Þ
1 q1
 
dx and
D
ðIIÞ
KLð gð yjxÞjjf ð yjxÞÞ ¼
Z 1
cp
g xð Þ p xð Þlog p xð Þ
q1
þ 1 p xð Þð Þ log 1 p xð Þ
1 q1
 
dx respectively
D
ðIÞ
KLðð gð yjxÞjjf ð yjxÞÞ ¼
Z cp
0
g xð Þ p xð Þlog p xð Þ
q1
þ 1 p xð Þð Þ log 1 p xð Þ
1 q1
 
dx
¼
Z cp
0
g xð Þ p xð Þ log p xð Þdx
Z cp
0
g xð Þ p xð Þ log q1dx
þ
Z cp
0
g xð Þð1 p xÞð Þ log 1 p xð Þð Þdx
Z cp
0
g xð Þð1 p xÞð Þ log 1 q1ð Þdx
Calculate ddq1 D
ðIÞ
KLð gð yjxÞjjf ð yjxÞÞ ¼  1q1
R cp
0 g xð Þ p xð Þdx þ 11q1
R cp
0 g xð Þ 1 p xð Þð Þ dx
Setting equal to zero and solving with respect to q1, we then obtain
q1 ¼
R cp
0 gðxÞ p xð Þ dxR cp
0 gðxÞ dx
Following the same calculations for D
ðIIÞ
KLð gð yjxÞjjf ð yjxÞÞ and solving with respect to q2, we get q2 ¼
R 1
cp
gðxÞ p xð Þ dxR 1
cp
gðxÞ dx
3.2 Estimation of the cutoff
The estimation of the cut-oﬀ cp is not straightforward and can be done by using numerical minimization. To do
this we need to repeat the calculations above for all possible values of cp and to ﬁnd the step model that minimizes
DKLð gð yjxÞjjf ð yjxÞÞ.
4 R and SAS code
The R code is not included here due to the extent of the code and the R scripts are available upon request from the
corresponding author. The following is the SAS code that was used for ﬁtting the Bayesian model for Scenario 1
using a mixture prior with imprecise part (MixN). The code can be modiﬁed to include other prior speciﬁcations.
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PROC MCMC
data¼Data outpost¼Dataoutput
nbi¼10000
nmc¼30000
thin¼50
seed¼seed
monitor¼(p1 p2 cp I w);
by dataID; # this is used for the simulated data; otherwise is omitted if a single dataset is used.
PARMS cp1 cp2 p1 p2 w I;
prior cp1  uniform(1,15);
prior cp2  normal(5,sd¼1);
hyperprior I beta(1,1);
prior w  binary(I);
cp ¼ w*cp1 þ (1-w)*cp2;
prior p1  uniform(0, 1);
prior p2  uniform(p1, 1);
p¼ (X<¼cp)*p1 þ (X>cp)*p2;
model y binary(p);
RUN;
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Abstract
In clinical development, the selection of novel prognostic biomarkers has to be paired
with the evaluation of the clinical utility of the risk score deﬁned by these biomarkers.
Before we apply the selected markers into routine standard care, for classiﬁcation or
patient selection, a cutoff value must be assessed based on the positive (PPV) and
negative (NPV) predictive value. In this paper, we propose a Bayesian variable selection
method which incorporates information about the predictive values into the biomarker
selection process and simultaneously estimates the cutoff value on the risk score of the
selected markers. A step function is used to model the probability of response, such that
the cutoff and predictive values are parameters of the model. This model allows for a
pre-speciﬁcation of a minimum PPV (or NPV) in the variable selection algorithm. The
choice of different prior distributions is compared and discussed via simulation studies
and a real data application.
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1 Introduction
In disease screening and prognosis, markers that predict the risk of a disease are needed. The
selection of novel prognostic markers and the evaluation of their predictive accuracy can be
used to stratify patients according to future risk of an outcome. Therefore, identifying the
most promising biomarkers is of major importance in a clinical setting. From a Bayesian
perspective, biomarker (variable) selection is done by imposing a prior distribution on the
regression coefﬁcients. There are two main alternative choices regarding priors: discrete
mixture priors or shrinkage priors. However, in a Bayesian setting, the selection of the
non-zero coefﬁcients is done ad hoc, since the probability that the value of an effect
is exactly zero is always zero. Among many methods, a popular choice is setting an
appropriate thresholding criterion on the posterior inclusion probability of each variable1
or by examining if zero is included in the credible interval for each of the effects2,3.
Other methods for choosing variables or models can be constructed using decision theoretic
arguments4.
After a set of markers is selected, a prognostic factor or risk score must be deﬁned and its
predictive accuracy must be evaluated before it is adopted for clinical screening or patient
selection. The most popular accuracy measure used in clinical literature is the area under the
ROC curve (AUC)5,6, which is a summary index of two accuracy metrics: the true positive
rate (TPR) or sensitivity and false positive rate (FPR) (1-speciﬁcity). However, neither
the AUC nor sensitivity and speciﬁcity reﬂect the ability of predicting the future outcome
conditional on the risk score. In contrast, measures such as positive and negative predictive
values (PPV and NPV) are clinically relevant quantities that we can directly interpret in
terms of the probability of disease given a positive or negative test result. Because predictive
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2 Medical and Pharmaceutical Statistics Research Unit Department of Mathematics and Statistics, Lancaster University, Lancaster
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values are functions of sensitivity, speciﬁcity and the prevalence of the disease, a risk score
with high sensitivity and speciﬁcity, and thus a high AUC, can have poor PPV when applied
to low prevalence populations7.
Another key factor to a successful drug development project is the identiﬁcation of the
patient population most likely to respond to a treatment or predict a person’s disease state.
Because drugs are only clinically useful and effective for patients below or above a certain
risk score, a reliable cutoff value (on the risk score) is needed in order to classify patients
according to their probability of response. Commonly used strategies for cutoff selection are
based on summary indexes mentioned above (i.e. desired sensitivity or PPV) as for example,
using the Youden index8 or the PSI index9. These measures are used to select a cutoff on
a pre-deﬁned risk score (of pre-selected variables). In other words, classiﬁcation and cutoff
selection are implemented using a two stage procedure; ﬁrst perform variable selection and
compute a risk score out of the selected features and then at a second stage, select a cutoff.
However, with this approach the selected features are not necessarily the ones that would
guarantee a minimum classiﬁcation performance, as the optimization is done under different
objective functions, i.e. at the ﬁrst stage, variable selection is done using a logistic model
and at the second stage, the estimation of the cutoff is done by ﬁtting a step function10.
Instead, information regarding target classiﬁcation measures should be included also in the
objective function of the ﬁrst step in order to optimize the balance between i) the desired
accuracy measures and ii) the sparsity of the resulted model. In most parts of this paper, we
consider the PPV over the NPV as the most important measure. However, this assumption
is not crucial for the methodology explained below.
In this paper, we propose a Bayesian method that combines the properties of variable
selection, with the advantages of using a step function to model the probability of response
for classiﬁcation purposes. By using the step function the predictive values and the cutoff
are now parameters of the model. If a target response rate is required by researchers, e.g.
PPV should only take values above a pre-determined lower value, it can be efﬁciently
incorporated in the variable selection algorithm. By restricting either the PPV or the NPV
values of the test in a pre-speciﬁed interval through the selection of the prior, we are able to
select those features that satisfy the restriction.
Prepared using sagej.cls
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In section 2, we introduce the hierarchical Bayesian model for variable selection that take
into account the predictive values of the risk score which is calculated from the selected
variables and present the model that controls one of the predictive values. The model
that assumes a step function to model the probability of response is a very useful way to
classify individuals based on their response rates. A particular interest lies in the posterior
distribution of the cut-off and predictive values. On the one hand, it gives guidance on the
choice of the cut-off value, and, on the other hand, provides information on whether the
assumed constraints on the predicitve values can be put in practice. We already note at this
point that the posterior estimates for the cut-off and predictive values fundamentally deviate
from the true model parameters, because the ﬁrst has to be conditional on the values of the
selected biomarker coefﬁcients in the ﬁnal risk score.
In section 3, we conducted a simulation study to investigate the behavior of different
shrinkage priors on the regression coefﬁcients as well to compare the behavior of the
proposed model under mispeciﬁcation. We use MCMC methods to estimate the posterior
parameter distributions and the posterior inclusion probabilities for the predictors. A real
data example is presented in section 4 before we conclude with some discussion.
2 Methods
2.1 Bayesian hierarchical model for variable selection
In this section we present a Bayesian model for simultaneous variable selection and cutoff
estimation of a risk score, as well as its predictive values. Suppose we have data (X, y),
where y = (y1, y2, ..., yn) is the binary response variable, with yi ∈ {0, 1} for all i =
1, ..., n and let X = (X1j, X2j, ..., Xnj) denote the n× d matrix of j = 1, ..., d predictors
(biomarker measurements) for n individuals and assume that X is measured on all patients.
We will assume that the n observations are independent and the predictors are standardized
to have mean zero and standard deviation one.
We consider the risk score Z to be a linear predictor, i.e. η = Z = XTβ, where β are
the regression coefﬁcients. As in10, we assume that the probability of response p can be
modeled by a step function that assumes constant positive and negative predictive values
when the risk score is above or below a speciﬁc cut-off. With this assumption, the predictive
Prepared using sagej.cls
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values and the cutoff are now parameters of the model, respectively. The positive predictive
value is deﬁned as the conditional probability of response given a positive test result, i.e.
P (Y = 1|T+). Conventionally, the test is positive, T+, if the biomarker exceeds a certain
cutoff cp, and is negative otherwise. Similar statements apply for the negative predictive
value which is deﬁned as the conditional probability that an individual is a non-responder
given a negative test result, i.e.P (Y = 0|T−). For further details about the model see10.
For the risk score Z = XTβ, the positive predictive value is deﬁned as PPV (cp) =
P (Y = 1|Z > cp) and the negative predictive value is deﬁned as P (Y = 0|Z ≤ cp). As
model parameter we will use the complementary of the NPV, namely 1−NPV (cp) =
P (Y = 1|Z ≤ cp) will be used. The Bayesian hierarchical model for variable selection and
classiﬁcation is speciﬁed as
Y |X ∼ Bernoulli(p)
p = P (Y = 1|Z = XTβ) =
{
p1 = P (Y = 1|Z ≤ cp) if XTβ ≤ cp
p2 = P (Y = 1|Z > cp) if XTβ > cp
(1)
β ∼ F
cp ∼ Uniform(a, b)
p1 ∼ Uniform(0, 1) and p2 ∼ Uniform(p1, 1)
where F is a prior distribution for the coefﬁcients. The different choices of prior will
be discussed in the following subsection 2.2. The cutoff cp is a parameter lying in a
bounded interval [a, b] strictly included in the support of the risk score Z. The parameter
p1 = 1−NPV expresses the probability of response given that Z is below the cutoff value
cp and p2 = PPV expresses the probability of response given that the value of XTβ is
greater than cp.
The primary question that arises in a clinical setting is the selection of a set of biomarkers
that fulﬁll a speciﬁc target, concerning the clinical utility of the test. Therefore, variable
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selection is done subject to pre-determined lower bound on positive predictive value (PPV)
of the biomarker-based test. For example, the selection of biomarkers shall satisfy the
restriction of a PPV above a threshold c2 or an 1−NPV below c1. This can be achieved by
restricting the priors of the variables on a subset of our choice. For example, non-informative
priors can be set as
p1 ∼ Unif(0, c1) or p2 ∼ Unif(c2, 1)
2.2 Prior speciﬁcation of the regression coefﬁcients
Many prior speciﬁcations have been proposed that try to shrink small coefﬁcients towards
zero and retain in the model only coefﬁcients with relevant larger effect sizes. Carvalho
et al.11,12 proposed the horseshoe prior (HS) for sparse signal detection, a hierarchical-
shrinkage prior for the regression coefﬁcients where the standard deviation is the product
of a local (λj) and a global (τ ) scaling parameter. It is given by
βj|λj, τ ∼ Normal(0, λ2jτ 2)
λj ∼ Cauchy+(0, 1) and τ ∼ Cauchy+(0, 1)
(2)
where theCauchy+(0, 1) is a standard half Cauchy distribution on the positive real numbers.
The global shrinkage parameter tries to estimate the overall sparsity level, while the local
shrinkage parameter is able to ﬂag the non-zero elements of β.
The spike-and-slab (SpSl)13,14 is a popular prior for sparse Bayesian estimation and is
often written as a two-component mixture of Gaussians. Here we consider that the spike
component concentrates its mass at zero whereas the slab component has its mass spread
over a wide range of plausible values for the regression coefﬁcients. Hence, we specify
a spike and slab prior for βj as f(βj) = (1− γj)fspike(βj) + γjfslab(βj) and the prior
inclusion probability γj ∼ Bernoulli(π) and π ∼ Unif(0, 1). Regarding the choices for
the fspike, usually is taken to be a delta spike (Dirac spike) at the origin δ0 and the fslab a
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normal density centered at zero. The prior for βj can then be written as
βj|γj, σ ∼ (1− γj)δ0 + γjNormal(0, σ2)
σ2 ∼ Inv −Gamma(as, bs)
(3)
The choice of the prior for the variance parameter is discussed in15. Here we considered
σ2 ∼ Inv −Gamma(1.5, 1.5) as mentioned in16. Instead of giving a continuous prior for
the slab component (i.e. as we do in the horseshoe for the local shrinkage parameter λj ),
here the only values allowed are γj = 0, 1. The spike and slab prior is modeling the inclusion
probability directly and therefore variable selection is based on the marginal posterior of γj
as we discuss in more details in section 2.3.
Park and Casella17 proposed the Bayesian Lasso by imposing the double exponential
prior (DE) on the regression coefﬁcients β with the density given by f(β) =
∏d
j=1
λ
2
e−λ|βj |.
When the shrinkage parameter λ has a gamma prior, the posterior mode of the double
exponential prior has a straightforward interpretation since it corresponds to the frequentist
Lasso estimates18. Several other choices have been proposed for the shrinkage parameter
λ, as mentioned e.g. in Lykou et al.19. As discussed by Hans20 and adopted in this paper,
the choice for the hyperprior on the shrinkage parameter λ, belongs to the class of gamma
priors. The model is speciﬁed as
β ∼ DE(0, 1/λ) and λ ∼ Gamma(c, d)
Under such continuous priors, like Laplace and HS the posterior probability of hitting
the exact value zero is always zero, so some appropriate thresholding procedure needs to
accompany the Bayesian procedure. The choice of the threshold is discussed in the following
section 2.3.
2.3 Bayesian Variable selection and thresholding
To set up the Bayesian lasso variable selection, we consider the model given in (2)
incorporating also the binary variable inclusion indicators γ = (γ1, γ2, . . . , γd)where γj = 1
indicates presence, and γj = 0 absence of covariate j, j = 1, . . . , d) as suggested in21 and19.
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The formulation for the risk score is now Z∗ = XDγβ, with Dγ = diag(γ1, γ2, . . . , γd) and
variable selection will be based on the marginal posterior variable inclusion probabilities
f(γj = 1|y) for j = 1, ..., d, quantifying the posterior importance of each covariate. For the
spike and slab prior, inclusion probabilities are calculated based on the marginal posterior
f(γj = 1|y) where γj = 1 when βj is allocated to the slab component as formulated in (3).
For the horseshoe prior, which does not directly implement variable selection but
shrinkage, one suggested threshold for variable selection is, to call βj a signal (i.e. βj = 0) if
γj := 1− 11+λ2jτ2 ≥ 0.5, and to call it noise otherwise
12. For all the prior speciﬁcations, we
estimate the posterior inclusion probability by the proportion of draws in the overall MCMC
chain (excluding burn-in) that include the predictor βj . Covariates are included in the model
if the posterior inclusion probabilities are greater than 0.5 as suggested by Barbieri and
Berger1. The authors provide arguments for the selection of the median probability model,
deﬁned to be the model containing all variables with f(γj = 1|y) ≥ 12 , which was found to
be the best model with regard to prediction performance.
2.4 Cutoff estimation and selection
After selection of the variables and estimation of the selected regression coefﬁcients βˆ we
are interested in the posterior distribution of the biomarker cutoff cp in order make a good
selection cˆp, e.g. by computing the posterior mean. For this we could simply use the marginal
of the joint posterior distribution. However, this distribution does not account for the speciﬁc
choice of variables and regression coefﬁcients that build the risk score to be used in future.
Therefore, a better approach is to consider the conditional posterior distribution of cp given
the now ﬁxed set of variables and βˆ. This can be done using MCMC with Gibbs sampling
considering βˆ (with zeros for the de-selected variables) as given just like the data Y and X .
To summarize, we estimate the risk score and its cutoff in two steps: in the ﬁrst step
we apply the model (1) and we perform variable selection based on the marginal posterior
inclusion probabilities f(γj = 1|y) ≥ 12 . Then we derive an estimate for the coefﬁcients
from their marginal posterior distribution, e.g. the posterior means βˆ. At a second step, we
apply the Bayesian procedure with the step model in (1) and same prior for p1, p2 and cp but
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now for the ﬁxed βˆ (see Vradi et al.10). The resulting (marginal) posterior distribution of cp
can now be used for the ﬁnal choice of cˆp, for instance, by taking the posterior mean.
3 Results
3.1 Simulation setting
In order to examine the performance of the proposed method, we conducted a simulation
study, where interest lies in correct selection of regressors as well as incorrect selection of
the unimportant variables. For each of the seven scenarios that we consider, we generated
1,000 data sets each with n = 200 individuals and varying number of predictors where
we applied all the methods. We consider a classiﬁcation problem with standard normally
distributed predictors X ∼ MVN(0,Σ), where Σ is the covariance matrix. Let ρ denote
the correlation between variables Xl, Xr where l, r ∈ 1, . . . , k, l = r. The response y is a
Bernoulli realization with probability p as it is deﬁned in (2.1) for given p1,p2 and cut-
off cp when a step model is used to generate the data, otherwise a logistic function is
used with logit(p) = XTβ. The true model that was used to generate the outcome has k
informative covariates Xj, j = 1, ..., k, k ∈ N, 1 < k < d. The noise variables are denoted
as m1, . . . ,md−k.
In scenario 1, we assume that there is only one informative predictor (k = 1)
in the dataset and m = d− k = 5 uninformative variables with β = (2, 0, ..., 0︸ ︷︷ ︸
5
). In
scenario 2, the data are generated using a logistic function for the probability of
response and we assume that there are m = 10 uninformative predictors in the model
and no important variables, i.e. the null model. In scenario 3, the total number of
predictors is d = 20 with m = 15 uninformative and β = (0.7, 1.5, 1,−2,−0.5, 0, ..., 0︸ ︷︷ ︸
15
).
The correlation ρ between the informative predictors is 0.7. In scenario 4, there are
d = 15 predictors with k = 5 informative ones and β = (1.5, 0.7, ..︸ ︷︷ ︸
2
,−1, ..︸ ︷︷ ︸
2
, 0, ..., 0︸ ︷︷ ︸
10
). The
correlation ρ between the informative predictors is 0.5. For scenario 5, the data are generated
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Table 1. Seven simulation scenarios for varying number of predictors, informative and non-informative, and varying
correlation among the informative predictors. The true cut-off cp, and predictive values p1 and p2 that were used to
generate the data are shown for scenarios 1, 3, 4 and 6 where we consider a step function as generating model. For
scenario 2 and scenario 5, the true generating model assumes a logistic function.
Scenarios
Generating
model
True cutoff
cp
True
p1
True
p2
Number of
Informative
predictors (k)
Number of Non-
Informative
predictors (m=d-k)
correlation
ρ = corr(Xl, Xr)
, l = r
1 step 1.5 0.20 0.85 1 5 0
2
(Null model) logistic - - - 0 10 0
3 step 1.5 0.30 0.80 5 15 0.7
4 step 1 0.20 0.85 5 10 0.5
5 logistic - - - 5 10 0.5
6
(2 stage) step 1 0.20 0.85 5 10 0.5
7
(2 stage) logistic - - - 5 10 0.5
assuming a logistic function and the k = 5 informative predictors have effect sizes β =
(1.5, 0.7, ..︸ ︷︷ ︸
2
,−2,−0.5, 0, ..., 0︸ ︷︷ ︸
10
) and correlation ρ = 0.5.
An additional method that we consider for a comparison, is the two stage (2-stage)
procedure described as follows; the algorithm ﬁrstly does variable selection assuming a
logistic model and at the second stage, considering the selected variables from stage one,
estimates the cut-off and predictive values by ﬁtting the step function model. For this
scenario, scenario 6, we consider the data in scenario 4 and ﬁt the 2-stage algorithm.
Similarly, in scenario 7, we implement the 2-stage approach on the data generated in
scenario 5, where we assumed a logistic function to model the probability of response. The
different simulation scenarios are summarized in Table 1.
Implementation of the methods was done in R version 3.4.322. The analysis was done
using Gibbs sampling with the library “R2jags”23 together with the JAGS software24. For
the MCMC, we used a burn-in of 2,000 iterations and keep the remaining 7,000 runs. We
compared results for the three different priors, the Laplace, the horseshoe and the spike-
and-slab prior. The 2-stage approach that we consider in scenario 6 and scenario 7, differs
from the proposed method at the following important point: at the ﬁrst stage the ﬁtted model
assumes a logistic function instead of the step function.
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3.2 Simulation results
In this section we present results of the simulation study for all scenarios regarding i)
posterior inclusion probabilities for the variables and ii) average number of True Positive
(TP) and False Positive (FP) over the simulation runs of the covariates that are correctly
and falsely included in the model. The TP and FP are deﬁned as the number of important
covariates correctly included in the model (i.e. variables with βj = 0) and the number of
covariates included in the model although their true effects are zero, respectively. The results
presented here are for the constrained PPV in the interval [0.8, 1] for all scenarios but 1 and
3. For scenario 1, we examined the behaviour of our method in the case that the lower bound
of the constraint is equal to the true generating p2, i.e the lower bound for the ﬁtted model
on the prior for p2 was 0.85. For scenario 3, where the difference in the response rates is
smaller than the other scenarios (i.e a higher p1 and lower p2), we took a lower bound for p2
equal to 0.75 (such that it does not coincide with the true value of p2).
Figure 1 shows the posterior inclusion probabilities over the simulation runs for all the
variables in the model and for the three prior speciﬁcations (Laplace, HS and SpSl). We
report the median together with the 1st and 3rd quartile. In Table 2, we present the average
number of TP and FP over the simulation runs for the correctly and falsely included variables
in the model for all scenarios and for all the different priors we considered. We expect the
TP to be as close as possible to the number of informative predictors k. Only for the null
model in scenario 2 (that there are no important variables in the model), the TP is the average
number that no variable was selected ( i.e. the average of the correctly selected null models)
and the FP is the average that at least one variable was included in the model.
As we see in Figure 1, when the covariates are not correlated (scenario 1) the important
predictors have always a very high posterior inclusion probability for all prior speciﬁcations
and the non-informative variables have always a low inclusion probability (< 0.5), except
the HS prior for which the median of the inclusion probabilities for the noisy predictors
is close to the inclusion threshold. Speciﬁcally, in all scenarios, the Laplace prior results
in higher posterior inclusion probabilities for the non-informative predictors, resulting in
larger models. On the other hand, the SpSl prior has low inclusion probabilities for the noisy
predictors, thus favoring sparser models, and further including the informative predictors
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with high probability. As we see in Table 2, all the priors tend to behave similarly regarding
TP in all scenarios. The Laplace prior results in higher number of FP, especially when the
predictors are i) highly correlated (scenario 3) and ii) the data are generated from a logistic
model and ﬁtted with the step function (scenario 5).
In scenario 2, the HS has higher inclusion probabilities than the Laplace and SpSl, but all
the priors have inclusion probabilities below the threshold value, i.e. correctly select the null
model. All priors behave well in the case of the null model and under misspeciﬁcation (i.e.
data are generated by a logistic model and ﬁt with a step model), resulting on average in
high TP and low FP (see Table 2). For scenario 3 where there is high correlation among the
informative predictors, some noisy variables are more frequently included. This seems to be
especially true for the Laplace prior that tend to select more often uninformative variables.
Overall, we see that the proposed method selects the correct model with high probability,
i.e. high TP and low FP, for all the priors, however, some priors tend to include some more
noisy variables than others.
[Insert Figure 1]
For scenario 5, where the ﬁtted model (step function) is divergent from the true generating
model (logistic function), we see that the important variables have a high probability of
inclusion for the Laplace and SpSl priors, but the inclusion probability (for the important
variables) is lower for the HS prior. We need to mention that with the Laplace prior we
more often include noisy variables as with the other priors. When we compare it with the
corresponding 2-stage approach in scenario 7 (where the ﬁtted model (at the ﬁrst stage) is
the same as the true data generating model, i.e. a logistic function), we see that all the priors
behave similarly for excluding the noisy predictors. However, for the 2-stage approach the
variables X2, X3 and X5 which have a weak effect, are not always included in the ﬁnal
model. Therefore the proposed method assuming the step function results in higher TP (i.e.
including on average more important covariates in the model).
The performance of the model in terms of predictive values, was assessed on a validation
dataset, where data were generated as described in section 3.1 under the different scenarios
for a sample size of n˜ = 10, 000. Taking the estimated βˆ and estimated cutoff cˆp (by
applying the proposed method), we deﬁne as p˜2 = P (y˜ = 1|X˜T βˆ > cˆp) and p˜1 = P (y˜ =
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Table 2. True Positives (TP) and False Positives (FP) over the 1,000 simulation runs for models we considered with
different prior speciﬁcations, Laplace, Spike and Slab (SpSl) and Horseshoe prior (HS). TP is the average number of
variables included in the model with βj = 0, and FP is the average number of non-important variables selected. The
second column in the table is the number of informative predictors (k) and non-informative predictors (m = d− k)
that were used to generate the data. For the null model in scenario 2, the TP are the average number that no
variable was selected (the null model).
TP FP
k m=d-k Laplace SpSl HS Laplace SpSl HS
Scenario 1 1 5 1 1 0.926 0.155 0.124 0.599
Scenario 2 0 10 0.879 0.943 0.849 0.121 0.057 0.151
Scenario 3 5 15 3.834 3.965 3.533 2.951 1.878 1.679
Scenario 4 5 10 4.951 4.933 4.641 1.449 0.718 0.376
Scenario 5 5 10 4.141 4.033 3.423 2.797 1.562 0.71
Scenario 6 (2-
stage)
5 10 4.411 4.314 4.343 1.351 0.66 0.299
Scenario 7 (2-
stage)
5 10 3.85 3.654 3.835 0.943 0.39 0.296
1|X˜T βˆ ≤ cˆp), respectively, where X˜ is the matrix of the biomarker measurements of the
validating set. In Figure 2, we present the boxplots of p˜1, p˜2 over the simulation runs.
For scenario 2, we did not report any results, because in the case there are no biomarkers
selected, then no cutoff is estimated and thus no classiﬁcation is taking place.
[Insert Figure 2]
The bias of the predictive values calculated as Bias(p1) = E(pˆ1 − p˜1) and respectively for
p2, is shown in Figure 3. As we see from the plot, the estimators of p1 are nearly unbiased
in all scenarios and for all priors. For p2, we observe slightly higher bias especially with the
HS prior. In Figure 3 we observe a tendency to slightly overestimate p2 and underestimate
p1.
The classiﬁcation ability of the model was assessed on the validation set described above
and we use the Brier score25 a measure of prediction accuracy that is calculated as
Brier =
1
n˜
n˜∑
i=1
(pˆi − y˜i)2
where pˆ = pˆ2 if X˜T βˆ > cˆp and pˆ = pˆ1 otherwise, where X˜ is the matrix of the biomarker
measurements of the validating set. In Figure 4 below we show the average Brier score over
the simulation runs. As we see, in all scenarios the average Brier score is close to 0.18 for
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the Laplace and SpSl and slightly higher for the HS prior. In the case of high correlation,
the Brier score is close to 0.25 indicating a not desirable classiﬁcation performance.
[Insert Figure 3]
[Insert Figure 4]
4 Real data application
We apply the proposed Bayesian method to a real dataset taken from a study as described
in Vradi et al.26. The data consist of d = 187 protein measurements at baseline for n = 53
patients. The outcome is response to a treatment, y ∈ [0, 1] andthe covariates are renamed
as X1, . . . , X187 to keep conﬁdentiality. The aim of the analysis is to classify patients
based on their biomarker measurements. The selection of the important variables satisfy
the constrain that p2 ∈ (0.8, 1). We apply our proposed Bayesian method and compare the
different priors, Laplace, SpSl and HS with the corresponding 2-stage approaches. For the
cutoff and predictive values we used Uniform priors. We run the MCMC algorithm with
Gibbs sampling for 100,000 iterations after a burn-in of 40,000 draws.
The Laplace prior selected 11 variables in the ﬁnal model, whereas the SpSl prior resulted
in the biggest model by including 78 proteins. The Horseshoe prior included 63 proteins
in the ﬁnal model and the 2-stage HS selected 72. In Figure 5 we present the posterior
inclusion probabilities for the variables selected. We order the proteins selected by the SpSl
prior according to their inclusion probabilities in decreasing order and keep the ﬁrst top
10. Further we matched these 10 proteins to the variables selected by the other priors. We
observed a signiﬁcant overlap between the selected proteins with the four methods.
The lightest color on the heatmap represents lower inclusion probabilities and the darkest
colors depict higher inclusion probabilities. In case that a variable was selected by the SpSl
prior but was not selected by another prior, the heatmap has a white color, i.e. this is the
case for the HS approach where only six variables where matched. In Figure 6 we plot
the posterior median for the predictive values p1, p2 and the cutoff cp together with the
95% credible intervals. The different priors result in deviating number of selected variables
(and estimated coefﬁcients βˆ), and therefore the estimated cutoffs cp cannot be directly
compared. The SpSl prior, which showed overall good performance in the simulation setting,
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is the only case where the lower bound of the 95% credible interval of p2 is different from
the imposed lower bound of the constraint and thus p2 is more informative.
[Insert Figure 5]
[Insert Figure 6]
5 Discussion
In clinical development, drugs are only clinically useful insofar as clinicians know for
which patients the treatment should be used. The utility of novel biomarkers and clinical
information for predicting patient prognosis and future outcome has great potential for
advancing treatment decisions in personalized medicine. In most clinical applications, we
face the problem of performing variable selection in order to reduce the complexity of the
resulted model. However, the selection of biomarkers must be based on criteria of selecting
those features that maximize either the positive or the negative predictive value. Together
with the selection of the important variables in the model, a risk score and a cutoff value
must be determined that will be used in practice for clinical decision making.
The Bayesian approach that we suggested for variable selection and cutoff estimation has
the advantage that we can control the predictive values of the risk score. This is done by
restricting the sample space to a range of desired values via the prior. The models presented
in this article are based on the use of shrinkage or mixture priors and selection of the
important variables is done ad hoc based on the posterior inclusion probabilities γj . In order
to estimate the cutoff (and the predictive values), we ﬁt the model assuming the step function
but now at the second stage by ﬁxing the estimated effects βˆ. We compared the proposed
method with an alternative 2-stage approach, where at the ﬁrst stage we ﬁt a logistic model
to select the informative variables and at a second stage we ﬁt the step model for cutoff
estimation.
Simulation results showed very good performance of the proposed method in terms of
correct variables included in the model. Even when the ﬁtted model (step model) is divergent
from the true generating model (logistic model) the proposed method performs well, in
terms of true positive rates of the variables. We found that when the true effect size is low
(i.e. < 0.5), and especially in case of high correlation, predictors tend to not be selected in
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the ﬁnal model. The Laplace and SpSl prior behaved well in the scenario of the null model
where very rarely selected any variable. Overall, across all scenarios and for the proposed
method, we found that the SpSl prior behaved better that the other priors, in terms of high TP,
low FP, low bias and good classiﬁcation performance. We observed a tendency to slightly
underestimate p2 and overestimate p1, but the bias was found overall small.
Obviously, the correlation structure of the covariates has an effect on the posterior
inclusion probabilities. When regressors are correlated, all priors we compared tend to not
identify all the important variables in the model, and some noisy variables are included
more often. Thus, the classiﬁcation error is also higher, compared to the situation when
predictors are independent or there is a low correlation dependency. On the other hand,
with correlated biomarkers, the selection of noisy biomarkers is not as severe as with
independent biomarker, because the noisy ones will then mediate some effect of the
correlated informative variables.
In this paper, we used as a risk score the linear predictor Z = η = XTβ, but of course,
any transformation of Z can be considered. To avoid dependency on the scale upon which
the continuous biomarker is measured, instead of using the raw values of the factor, we
could standardize the scale by using the empirical distribution function (ecdf) of the risk
score Z. For a vector Z = (z1, z2, . . . , zn) the empirical distribution function is Fn(Z) =
1
n
∑n
i=1  zi≤z, with   the indicator function. For any u ∈ (0, 1) we can deﬁne a biomarker
positive result if F−1n (u). Therefore, the assumption of a monotonic function for PPV
and NPV is imposed to reﬂect the rationale for classifying subjects based on a binary
classiﬁcation rule. Instead of the ecdf, another proposal is to use the probit model with
P (y = 1|X) = Φ(XTβ), Φ is the cumulative distribution function of the standard normal
distribution.
Strong prior scientiﬁc knowledge is typically rare in biomarker identiﬁcation problems,
but when it is present (i.e. historical data or literature) it can be very easily incorporated.
The new classiﬁcation strategy is designed to guarantee a pre-determined predictive value
(e.g. PPV of at least 80%). Attention should be paid in the case that the selection of a set
of variables with pre-speciﬁed predictive values is not achievable due to the relationship
between the risk score and the response. Our empirical results indicate that the method will
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result in a posterior distribution of the restricted parameter that has a mode on the bound of
the interval (here the lower bound). Hence, we expect that a data conﬂict with respect to the
pre-speciﬁed minimal predictive value can be realized from the behaviour of the posterior.
Moreover, the choice of the shrinkage prior plays a crucial role in Bayesian variable
selection, where many suggestions have been proposed to achieve sparsity, as for example,
the horseshoe+27, the R2-D2 prior28, Dirichlet-Laplace priors29 which belong within the
class of global-local shrinkage priors. The behavior of the model under other choices of
prior distributions as well as different choices on the hyperprior parameters is worth further
exploration.
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Appendix
In Figure A1, we present the average brier score for all scenarios and the different priors
for varying sample sizes of n = 50, 100, 200, 500. The classiﬁcation ability of the model
was assessed on a validation dataset, where data were generated as described in section
3.1 under the different scenarios for a sample size of n˜ = 10, 000. Taking the estimated βˆ
and estimated cutoff cˆp (by applying the proposed method), the Brier score is calculated as:
Brier = 1
n˜
∑n˜
i=1(pˆi − y˜i)2, where pˆ = pˆ2 if X˜T βˆ > cˆp and pˆ = pˆ1 otherwise, where X˜ is the
matrix of the biomarker measurements of the validating set. In the plot below we show the
mean Brier score over the simulation runs.
[Insert Figure A1]
For scenario 2, we did not report the Brier score, because if there are no biomarkers, then
no cutoff is estimated and thus no classiﬁcation is taking place. For Scenario 3, where the
correlation among informative predictors is high, we observe the highest error for all the
priors. The HS prior resulted in the highest error in all scenarios, but the 2-stage approach.
This result could be expected, as the HS prior did not perform well in selecting the true
variables in the model (see Figure 1 and Table 2).
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Figure 1. Posterior inclusion probabilities f(γj |y) for all scenarios 1-7 over the 1,000 simulation runs. The dots are the medians of the posterior
distribution together with the 1st and 3rd quantiles. In blue is the spike and slab prior, the Laplace prior in green and the horseshoe prior in red. On
the horizontal axis are all the variables in the model, informative (X) and non-informative (m). The black horizontal line corresponds to the value 0.5
that is considered as threshold for including a variable in the model.
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Figure 2. Boxplots of the p˜1,p˜2 (true values for the selected biomarkers scores) for all priors, HS (left boxplots) Laplace (middle boxplots), SpSl
(right boxplots) and for all scenarios except the null model (scenario 2). The horizontal solid red line is the lower bound on p2 that was used in the
estimation procedure. The horizontal dashed black line is the value of p1, p2 that was used to generate the data. For scenario 5 and 7 the generating
model uses a logistic function and therefore there is no generating p1, p2 are deﬁned.
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Figure 3. Boxplots of the pˆ1 − p˜1 (left panel) and pˆ2 − p˜2 (right panel) over the 1000 simulation runs for all priors, HS (left boxplots) Laplace
(middle boxplots), SpSl (right boxplots) and for all priors and for all scenarios except the Null model (scenario 2).
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Figure 4. Plot of the average Brier score together with the 1st and 3rd quantile, over the simulation runs for all scenarios and for all priors, Laplace
(green triangle), SpSl (blue square) and HS (red dot).
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Figure 5. Heatmap of the inclusion probabilities of the top 10 variables selected. The selection of the top variables was done by ordering the
inclusion probabilities of the variables selected by the SpSl in decreasing order and then matching these variables with the selected ones by Laplace,
HS and HS (2-stage) prior. The Laplace (2-stage) and SpSl (2-stage) approaches resulted in selecting the null model. The white color on the heatmap
indicates that some variables selected by the SpSl prior were not selected by the other priors.
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Figure 6. Plot of the posterior medians together with the 95% credible intervals for the predictive values p1, and p2 (left panel) and the cutoff cp
(right panel). On the vertical axis are the different prior, Laplace, SpSl and HS. Results for the Laplace (2-stage) and SpSl (2-stage) approaches are
not reported as the selected model was the null model. The vertical dashed red line is the lower constraint used on p2.
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Figure 7. Plot of the average brier score together with the 1st and 3rd quantile, over the simulation runs for all
scenarios and for all priors, Laplace (green triangle), SpSl (blue square) and HS (red dot) and for sample sizes of
n = 50, 100, 200, 500.
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